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Breast cancer (BC) is now a disease that will affect 1 out of every 8 women worldwide. Due to 
its highly heterogeneous nature, BC is usually further classified into different subtypes according 
to gene expression profiling analysis. Basal-like breast cancer (BBC) accounts for 15-20% of all 
cases of BC. BBC is very aggressive, highly metastatic, and often lethal, mostly due to our poor 
understanding of the key genetic events that lead to the onset and/or maintain this subtype of BC. 
As a result, we currently lack targeted therapies that are otherwise very effective in some of the 
better understood subtypes of BC.  Therefore we set to work on deciphering the genetic 
alterations that when, expressed altogether, would model the onset of sporadic BBC in human 
cell lines. We already know that patients with BBC often display mutations in the tumor 
suppressor p53, as well as over-expression of the epidermal growth factor receptor (EGFR) 
protein by immunohistochemistry, and that loss of PTEN protein is also seen occurring along 
with the aforementioned lesions.  
 
However, there is no model for sporadic BBC that accurately reflects the genetic changes that 
BBC tumor samples display for studying this BC subtype progression and/or providing a base for 
which pharmacological studies can be done to find an effective therapy. Thus we used a non-
  
transformed immortalized mammary epithelial cell line, MCF10A, as our model and engineered 
cells with termed ‘triple modified’ cells that express the three aforementioned alterations (PTEN, 
EGFR, p53) that highly observed in BBC.    
 
Furthermore, as part of the goal to better understand the genetic underpinnings that occur in BBC 
progression, we investigated whether variant forms of EGFR existed in cell lines of the basal-
like subtype.  Prior studies have demonstrated that immunostaining for EGFR in BBC patient 
tumor samples is elevated, though the molecular mechanisms are not well understood.  EGFR is 
only amplified in BBC in less than 1% of cases thus gene amplification does not account for the 
high percentage of tumors that express and overexpress EGFR.  In the pursuit to better 
understand the possible contribution of deregulated EGFR in BBC, we discovered a variety of 
basal-like breast cancer lines containing genetic alterations in EGFR not yet reported in the 
literature and demonstrated that a portion of them stimulate growth, invasion and transformation 
in mammary cells. 
 
In conclusion, the studies on modeling basal-like tumorigenesis and identifying and 
characterizing novel variants of EGFR in basal-like breast cancer lines have shed new exciting 
insights into our current knowledge of BBC.  Having a cell line model for the disease provides a 
new tool for which further genetic and epigenetic manipulations can be exercised to continue 
asking questions of which other oncogenes and tumor suppressors are important for initiation of 
BBC.  Our data showing that EGFR variants can be found in BBC cell lines and alter breast 
epithelial growth shows that this is an area that should be further investigated in human tumors 
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Cancer cells arise when a normal cell suffers stepwise accumulations of different genetic 
alterations able to bypass the homeostatic mechanisms that govern normal cellular proliferation 
and migration. Once normal cells are transformed, they display different hallmark phenotypes 
that can be contributed to their oncogenic state – growth independent proliferation (their ability 
to grow without having growth factors around to signal for growth), loss of proliferation control 
(aberrant growth rate as compared to their normal cellular state), suppression of apoptosis, 
growth in an anchorage independent fashion (unlike adherent cells), immortalization of cells 
(loss of their normal signal to stop dividing after a certain number of passages and therefore 
growing forever), angiogenesis (the de-novo recruitment of blood vessels to the tumor site), 
invasiveness (ability to create local tissue destruction), and metastasis (ability to enter the 
circulatory system to spread) (Hanahan D and Weinberg RA, 2000). Additionally, genes whose 
alternations lead to cancer predisposition can alter other pathways such as cellular genomic 
maintenance, which once lost can cause genomic instability, another hallmark in cancer cells.  
Breast cancer is the second most common type cancer in the world and it affects 200,000 new 
cases in the United States alone each year (Ries et al, 2005).   
 
Breast cancer (BC) cannot be classified as one disease.  Gene expression profiling analysis of 
breast tumors demonstrates that BC, to be more accurately described, is further classified into 
five different subtypes due to differential expression of genes between them (Sorlie, Perou et al. 
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2001, Sorlie 2004).  The subtypes for breast cancer are: (1-2) Luminal A and luminal B that are 
estrogen receptor positive; (3) HER2+ that have amplification of HER2 receptor; (4) basal-like 
that express basal epithelial keratins; and finally (5) normal-like subtype (Sorlie, Perou et al. 
2001, Sorlie 2004, Cancer Genome Atlas 2012). Importantly, each subtype has its own histo- and 
clinical pathology and prognosis (Sorlie 2004). There is an increasing amount of literature in BC 
highlighting the extensive heterogeneity not only between all five subtypes, but also within each 
subtype (Cancer Genome Atlas 2012).  The challenge to treat each subtype of BC then becomes 
more difficult as we do not currently have a consensus for the alterations that can always 
accurately identify each subtype due to such high rate of mutation rate (Cancer Genome Atlas 
2012). Due to such high genetic and epigenetic possibilities that lead to each subtype of breast 
cancer, there is recognition for a need for personalized targeted therapy, depending on the prolife 
of each tumor.  
 
One of the worse subtypes of breast cancer to date is called the basal-like subtype of cancer 
(BBC).  This type of BC is characterized as being one of the most lethal and aggressive subtypes, 
metastasizing fast and having no targeted therapy for personalized treatment (Sorlie, Perou et al. 
2001, Sorlie, Tibshirani et al. 2003, Sorlie 2004). On the other hand, HER2+ amplified breast 
cancer has Herceptin as a very effective drug targeting the altered HER2 receptor that is the 
common denominator in all tumors in this subtype and thus this subtype has a very effective 
targeted therapy (Khasraw and Bell 2012).  However, for BBC, even though there are a few 
known genetic alterations that occur at high frequencies, BRCA1 mutations (~30%), PTEN loss 
(~15-50%), PIK3CA (7%) and TP53 mutations (>80%), there is no established common 
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disrupted pathway(s) that we know are responsible for tumor initiation in this lethal subtype 
(Cancer Genome Atlas 2012). 
 
The work done in this thesis has focused on delineating the genetic alterations that are not only 
physiologically relevant, meaning that they occur at a high frequency within the population of 
BBCs, but that they can be shown to initiate tumorigenesis.  The knowledge of which 
combination of tumor suppressors and oncogenes are able to model cancer initiation in cell lines 
will not only become a powerful tool to identify the pathways activated or deactivated in a BBC 
tumorigenesis model, but it can also allow for further studies of how BBC progresses, spreads 
and behaves to drugs therapies.  Therefore, one of the aims is to study the effect of the 
combination of alterations that occur at high frequency in BBC: loss of PTEN (phosphatase and 
tensin homolog deleted on chromosome 10), overexpression of EGFR (epidermal growth factor 
receptor), and loss of function of the tumor suppressor p53. We have also investigated one of the 
possible novel mechanisms for the high expression of EGFR in BBC – by analyzing cell lines of 
the BBC origin for gross alterations of this receptor. 
 
In brief, this thesis will provide a review of breast cancer, its genetics and subtypes, as well as a 
thorough historical approach to what is known about each gene that we study in our BBC 
modeling (PTEN, p53, and EGFR). Therefore, we go into details about each of their discovery, 
structures, functions, altered pathways, known mice/cell line models, and how each of these 
genes are altered in BC.  Following the Introductory chapter, we present our work on BBC cell 
line modeling in the second chapter, followed by the work on the discovery and characterization 
of EGFR variants in BBC cell lines in the third chapter.  In the last chapter, chapter IV, we 
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outline the discoveries of all the work performed in this thesis. We also present our concluding 












The breast gland mammary epithelium is derived from the embryonic epidermis during 
development of the fetus in utero in the first six weeks (Tavassoli 1999).  During puberty, it 
continues to grow and elongate from the terminal end buds into ducts and lobules surrounded by 
fatty tissue, also termed the stroma of the gland (see Figure 1.1) (2002). The breast gland is 
indistinguishable between female and male prior to puberty, after which released sex hormones, 
namely estrogen and progesterone, are catalysts for major changes in the breast epithelium to 
form the mature female gland (Figure 1.1).  In men, these changes are inhibited by the release of 
antagonizing sex hormone testosterone (Tavassoli 1999).   
 
There are four basic structures to the mature female breast: (1) The mammary milk ducts 
(composed of epithelial cells) that direct milk to be secreted at the nipple; (2) 15-20 lobules per 
breast that make up the site where milk is produced; these structures are surrounded by 
hormonally-responsive specialized periductal stromal cells composed of (3) supportive fibrous 

























Figure 1.1. The anatomy of the female breast.   
The post-puberty breast is made out of ducts and lobules surrounded by the stromal cells (fatty tissue).  
The nipple contains epithelial ducts that can secret milk. Adapted from Mayo Clinic 2011. 
 
The lobules and ducts are mainly made out of two epithelial layers – the luminal and the basal 
layer.  The luminal epithelium makes up the inner secretory layer, facing the lumen of the breast 
duct, whereas the basal epithelium lines the outer layer of the ducts and can contain contractile 
myoepithelial cells (Tavassoli 1999).  The two aforementioned epithelial layers can be 
distinguished typically by the differential expression of cytokeratins (CK).  Specifically, luminal 
epithelial cells express CK 8, 18 and 19 and basal cells express instead CK 5, 6, 14 and 17.  
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It is expected about 227,000 women will be newly diagnosed while approximately 39,500 
women are expected die of breast cancer yearly in the U.S.A. (Howlader N 2011).  Breast 
cancer-related deaths comes only after lung cancer among women (Ries LAG).  The lifetime risk 
of a woman developing breast cancer is one in eight, or 12.6% (Greenlee, Hill-Harmon et al. 
2001).  Men are diagnosed with breast cancer disproportionately less than women but there are 
still approximately 2,140 cases a year of men diagnosed while approximately 450 will die from 




Figure 1.2. Estimated new cases of breast cancer in female patients. 
Number of breast cancer patients per age group in the US in 2011.  
Adapted from the American Cancer Society (Surveillance Research 2011). 
 
 
Mortality rate for breast cancer are the highest among the oldest group of patients diagnosed with 
breast cancer (see Figure 1.2) (Cosgrove, Chotirmall et al. 2011).  It appears that the youngest of 
the population developing breast cancer have the more aggressive prognosis (Richie and 
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Swanson 2003).  Although chances of recurrence can occur up to 20 years after being treated, 
most recurrences (60-80%) occur in the first three years (Schapira and Urban 1991, McKay and 
Langlands 1992).  
 
Breast Cancer Genetics 
 
Cancer is caused by the stepwise accumulation of genetic and/or epigenetic alterations in genes 
that normally play important roles in the regulation of cell proliferation and whose deregulation 
can lead to uncontrolled cellular proliferation and cancer.  The alterations to the gene or 
regulation of a gene can be the result of different factors such as spontaneous, environmentally or 
chemically induced DNA damage.  Genes that affect the evolution of cancer are those that are 
involved in the following functions: (1) directly regulate cell proliferation by either inhibiting it 
or promoting it; (2) involved in the repair of DNA that has been damaged; (3) control apoptosis, 
or cell death capability (Hanahan and Weinberg 2000).  There are two classes of genes that 
involved in cancer genetics: tumor suppressor genes and oncogenes.   
 
Tumor suppressor genes can be defined as genes that encode proteins that normally inhibit the 
formation of tumors (Klein 1987).  Typically, two alleles of a tumor suppressor need to be lost or 
have lost its function for the gene to cause transformation.   Furthermore, tumor suppressor genes 
can be subdivided into two other groups: the gatekeepers or the caretakers (Kinzler and 
Vogelstein 1997).  Mutation in gatekeeper tumor suppressor genes, such as TP53 and RB, leads 
to transformation by directly releasing the ‘breaks’ on cellular proliferation and preventing cell 
death. On the other hand, however, caretakers are tumor suppressor genes that ensure genomic 
integrity. Caretaker genes, such as those involved in DNA repair, help in maintaining genomic 
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instability to prevent the accumulation of deleterious mutations, including other tumor 
suppressor genes and oncogenes.  Therefore, loss of a caretaker will indirectly affect and lead to 
tumorigenesis by allowing the accumulation of subsequent mutations. Oncogenes are genes that 
are growth promoting and thus will promote tumorigenesis if their activity is aberrant (Bishop 
1983).  For example, in breast cancer, HER2 and PIK3CA are well known oncogenes that are 
highly mutated in breast cancer (Cancer Genome Atlas 2012). Mutation in only one allele of an 
oncogene is necessary to lead to tumorigenesis and thus mutations in oncogenes are classified as 
dominant, unlike in tumor suppressors that are classified as recessive.  
 
In breast cancer, genetic and epigenetic lesions that are found in breast cancer are reported in an 
ever increasing body of literature with aim to understand how this type of tumor arises and 
progresses.  We currently do not know the initiating events or the sequential order in which the 
alterations occur in breast cancer due to such high heterogeneity that exists between different 
types of breast cancer and importantly, also within each subtype of this cancer (Cancer Genome 
Atlas 2012).  A few plausible reasons for the difficulty in deciphering the exact drivers of breast 
cancer from the passenger mutations as well as delineating the order in which they have to occur 
for the cells of the mammary epithelium to become transformed are: (1) high heterogeneity that 
is found across breast cancer tumors (the result of which is sub classifications or different 
subtypes of breast cancer) (Cancer Genome Atlas 2012), (2) high heterogeneity within each 
subtype that makes it difficult to predict and study the proper combinations of oncogenes and 
tumor suppressors that are sufficient to initiate and/or maintain tumorigenesis of breast cells 
(Cancer Genome Atlas 2012), (3) distinguishing which of the variety of low penetrance 
oncogenes and/or tumor suppressor genes are the ‘drivers’ from the ‘passengers’ given that very 
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few of the genes and proteins altered in each subtype occur at high frequencies (Cancer Genome 
Atlas 2012), and finally (4) the need to integrate models that consider both genetic and/or 





In breast cancer, as the case of other cancers, tumor suppressors genes typically have a mutation 
in one allele and a deletion of the remaining allele that is consistent with the ‘two-hit’ hypothesis 
that was proposed by Alfred Knudson (in reference to the tumor suppressor gene retinoblastoma, 
RB) (Knudson 1971).  However, in some cases, there may not be a mutation in one of the alleles 
for partial inactivation of a tumor suppressor; there are other mechanisms that lead to their 
inactivity or loss of expression.  Some of the possible ways, aside from a mutation, to inactivate 
a tumor suppressor allele are (1) abnormalities in the other proteins that interact with the tumor 
suppressor, (2) methylation of the promoter of the gene, or (3) increased rate of proteosomal 
degradation, to name a few (Osborne, Wilson et al. 2004). The ‘two-hit’ hypothesis states that 
both alleles must be lost to allow for the malignant phenotype to be unmasked. There are a few 
tumor suppressor genes that have been well characterized in breast cancer whose pivotal roles 




The TP53 tumor suppressor gene is located at 17p13.1 and it encodes a 393-kDa protein called 
p53. Mutation in this gene was detected in lung and colon cancers in 1989, and it has since then 
become one of the most well studied tumor suppressor genes probably due to TP53 being the 
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most mutated gene in all human cancers (Nigro, Baker et al. 1989, Takahashi, Nau et al. 1989).  
In breast cancer, TP53 is mutated in approximately 50% of cases, similar to the mutational rate 
of TP53 mutations in the rest of cancers (Hussain and Harris 1999). The role of p53 is to sense 
cellular stress such as DNA damage, oncogene over-expression.  As a gatekeeper of the genome, 
p53 is a transcription factor that regulates the expression of its target genes that regulate the cell 
cycle, apoptosis, DNA repair response and senescence (Sengupta and Harris 2005, Levine, Feng 
et al. 2006).  The Li-Fraumeni syndrome is a rare hereditary predisposition that stems from 
germline mutations in TP53 and whose patients have increased risk of a variety of cancers, 




Another important tumor suppressor gene that is highly recognized as an important gene in 
breast cancer is BRCA1.  This gene was identified in 1994, although earlier studies based on 
linkage analysis of families with multiple breast cancers had identified the locus 17q21 as being 
altered (Hall, Lee et al. 1990, Miki, Swensen et al. 1994).  BRCA1 encodes for a protein that is 
1,863 amino acids with various structural domains, including a RING finger domain that encodes 
for a protein-binding domain (Bienstock, Darden et al. 1996) that associates with BRCA-
associated ring domain (BARD1) for its tumor suppressive functions.  Interestingly, BRCA1 
mutations in the mammary gland give rise to breast cancers that are nearly always of the basal-
like subtype of breast cancer (more information on the subtypes of breast cancer is described 
below) (Sorlie, Tibshirani et al. 2003, Turner and Reis-Filho 2006, Da Silva, Clarke et al. 2007).   
More than 5% of all breast cancer cases in women under 40 years of age are those who carry 
BRCA1 mutations, although this statistics becomes much higher closer to 90% for cases that 
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arise in families with multiple cases of breast cancer (Ford, Easton et al. 1995, Ford, Easton et al. 
1998).   
 
Following genotoxic stress, BRCA1 responds by localizing to the areas of genomic damage to 
support DNA double-strand break repair in the cell along with Rad51 and BARD1 proteins 
(Scully, Chen et al. 1997).  BRCA1 has also been shown to be involved in transcriptional 
regulation, cell cycle checkpoint control, chromatin remodeling, X chromosome inactivation, 
ubiquitination, and centrosome regulation, aside from its DNA repair functions (Chapman and 
Verma 1996, Monteiro, August et al. 1996, Scully, Anderson et al. 1997, Anderson, Schlegel et 
al. 1998, Xu, Weaver et al. 1999, Scully and Livingston 2000, Welcsh and King 2001, Ganesan, 




BRCA2, located at 13q12.3 in the chromosome, is another important tumor suppressor in 
hereditary breast cancer (Wooster, Neuhausen et al. 1994, Wooster, Bignell et al. 1995, 
Tavtigian, Simard et al. 1996).  The risk for men developing breast cancer becomes higher when 
carrying BRCA2 mutation (Ford, Easton et al. 1998, Narod 2005).  In the U.S., this gene is 
mutated in only 4% of men with breast cancer, and like it is with BRCA1, sporadic mutations of 
BRCA2 are very rare (Friedman, Gayther et al. 1997).  Furthermore, having BRCA2 mutations 
means a person has a higher risk of developing other types of cancers, including melanoma, 
prostate cancer, and gastric cancer as indicated by the Breast Cancer Linkage Consortium 
(1997).  An important difference between breast tumors carrying mutations in BRCA2 or BRCA1 
is that BRCA2 tumors are often of lower grade and ER-positive (Lakhani, Van De Vijver et al. 
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2002), and on the other hand, BRCA1 breast tumors are mostly higher grade tumors and do not 
express estrogen receptor (ER) (Johannsson, Idvall et al. 1997). 
 
BRCA2 shares many features with BRCA1; however, their structures are dissimilar.  BRCA2 
has its own binding partner, Rad51, to function in the high fidelity phase of DNA repair that 
requires proofreading of chromatid templates for homologous recombination (Scully and 





PTEN encodes for a dual protein and lipid phosphatase that is a key negative regulator of 
oncogenic phosphatidylinositol 3-kinase (PI3K)-AKT pathway. When PTEN is lost, this pathway 
becomes unrestrained and the result is the hyper activation of the downstream key protein, AKT, 
that is responsible for cell survival, growth, proliferation, migration, genomic instability and 
associated with poor survival in carcinoma (Burke, Daly et al. 1997, Puc, Keniry et al. 2005, 
Saal, Johansson et al. 2007).  Upon heterozygous deletion of one of the Pten alleles in the 
mammary gland of mice, breast cancer arises that is characterized within the basal-like subtype 
of breast cancer (Saal, Gruvberger-Saal et al. 2008).  Less than 5% of breast cancer tumors have 
documented coding mutations in PTEN, however, about a quarter of all breast cancers are 
documented to have significant decrease of PTEN at the protein level by immunohistochemistry 
(Saal, Gruvberger-Saal et al. 2008), suggesting there are probably other unknown mechanisms 
by which PTEN is being down-regulated in breast cancer. The Parsons group showed in 2008 






Given the extraordinarily high level of heterogeneity within breast tumors, it becomes more 
difficult to identify oncogenes that are prominent in the majority of BCs, however, there are 
some candidates that have been well studied over time and shown to be influential in mammary 
tumorigenesis.  EGFR, one of its family members, HER2, as well as cell cycle modulator, cyclin 
D1 and the transcription factor MYC will be discussed in further detail for their important role in 





One of the most recognized oncogenes in breast cancer is HER2, a gene located on chromosome 
17q21.1 that encodes for the epidermal growth factor receptor (Schechter, Stern et al. 1984).  
Epidermal growth factor receptor (EGFR), or HER1, another tyrosine kinase receptor highly 
associated with breast cancer, is found on chromosome 7p12 (Ro, North et al. 1988).  These 
genes can be both amplified in breast cancer – however, while HER2 is amplified in 
approximately 25% of breast cancers, EGFR is only amplified in about 1% of them (King, Kraus 
et al. 1985).  The most well known mechanism for EGFR deregulation in breast cancer is its 
over-expression as measured by immunohistochemistry that can be as high as almost one third of 
all breast tumors (Spyratos, Delarue et al. 1990, Al-Kuraya, Schraml et al. 2004).   
 
HER2 was discovered in 1984 as a mutant form of a cellular gene derived from rat 
neuro/glioblastomas, called neu (Schechter, Stern et al. 1984).  Neu was found to encode for a 
tyrosine kinase receptor and to be a homologue of the avian erythroblastic leukemia viral 
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oncogene.  Furthermore, neu was found to be a homologue of the human EGFR (Schechter, 
Stern et al. 1984). 
 
Targeted therapy for breast cancer has been mainly successful for the HER2 receptor in patients 
with HER2-amplified tumors, whereas EGFR targeted therapy has not yet proven to be effective, 
as EGFR-over amplified breast cancers from patients whose tumors fall within the basal-like 
subtype still lack targeted therapy that can significantly hinder cancer progression.   HER2 
targeted therapy, such as humanized antibody trastuzumab, also termed Herceptin, works well to 
improve patient survival and reduce the recurrence of the tumor (Piccart-Gebhart, Procter et al. 
2005, Romond, Perez et al. 2005).   
 
Further information on EGFR and HER2 regarding their structures, their modes of activation, 
their specificity to ligands for receptor activation (or lack thereof for HER2), the proteins they 
interact with, and the downstream signaling pathways activated will be detailed in a later section 






An important gene that regulates the cell and is highly altered in breast cancer is CCDN1, which 
encodes for cyclin D1. CCDN1 is found on 11q13 in the chromosome and is amplified in about a 
quarter of breast cancers (Gillett, Fantl et al. 1994).  Breast tumors also over-express the protein 
product of this gene in approximately half of all patients with this disease (Ormandy, Musgrove 






MYC is a homolog of the avian v-myc myelocytomatosis viral oncogene, which is located on 
chromosome 8q24. This gene is amplified in about 15% of breast cancer cases (Escot, Theillet et 
al. 1986).  This oncogene is a transcriptional factor that regulates cell growth and it promotes cell 
cycle progression, metastasis, genomic instability, while inhibiting apoptosis (Bishop, Eilers et 
al. 1991, Eilers, Schirm et al. 1991, Felsher and Bishop 1999, Johnston, Prober et al. 1999, 
Pelengaris, Khan et al. 2002). 
 
 
Molecular Subtypes of Breast Cancer 
 
 
Breast cancer is a disease that, due to its highly heterogeneous nature, can be classified further 
down into five different subtypes according to gene expression profiling (Sorlie, Perou et al. 
2001).  Groups were also able to show that the different subtypes of breast cancer were clinically 
relevant and distinct, with their own patient outcome, therapy, and prognosis (Sorlie, Tibshirani 
et al. 2003).  The five different subtypes – ER+ luminal A, ER+ luminal B, basal-like subtype, 
HER2+, and normal-like – will be discussed in further detail below. Recently a new study by 
The Cancer Genome Atlas Network comprising of multiplatform analysis that has not yet been 
done yet was able to do a more extensive analysis of each subtype of breast cancer (Cancer 







This subtype is named ‘normal-like’ breast cancer because these tumors express clusters of genes 
that are also shared by the normal breast specimen by gene expression profiling (Perou, Sorlie et 
al. 2000).  This subtype of BC encompasses the least understood of all subtypes of breast cancer, 
fall within the ER- expressing tumors and generally has very low occurrence such that analysis 
of its molecular underpinnings is very difficult due to low statistical strength (Perou, Sorlie et al. 
2000) (Cancer Genome Atlas 2012).   
 
ER+ Luminal A and Luminal B Subtypes 
 
 
The BC subtype called Luminal A expresses the estrogen receptor (ER+).  In general, this 
subtype expresses the highest levels of ER status genes, aside from the ER receptor itself, as 
compared to the other ER+ luminal subtype B (Cancer Genome Atlas 2012). An important 
aspect of this subtype is that patients who have breast cancer of the luminal A subtype have 
relatively better prognosis compared to any of the other subtypes (Sorlie, Perou et al. 2001, 
Sorlie, Tibshirani et al. 2003).  In terms of mutations, luminal A subtype has approximately the 
highest percentage of PIK3CA mutations among all subtypes (45%), followed by mutations in 
TP53 (12%) and MAP3K1 (13%) (Cancer Genome Atlas 2012). Interestingly, luminal A subtype 
has the lowest mutation rate of all BC tumors, in contrast to the basal-like and HER2+ which 
have the highest (Cancer Genome Atlas 2012). 
 
 
The luminal B subtype, unlike luminal A, expresses less ER status genes, although it is still 
significantly more than the other subtypes (87% for luminal A and 82% for luminal B) (Sorlie, 
Perou et al. 2001, Cancer Genome Atlas 2012). However, both luminal A and B subtypes have 
been recently characterized as having more diverse and recurrent significantly mutated genes 
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than either the basal-like or HER2+ subtypes of breast cancer (Cancer Genome Atlas 2012).  
Prognosis for luminal B tumor-bearing patients is generally worse than luminal A tumor-bearing 
patients (Sorlie, Perou et al. 2001).  Luminal B breast cancers express 29% of TP53 mutations as 
well as the same percentage of tumors that have PIK3CA mutations (Cancer Genome Atlas 






The basal-like subtype of breast cancer was identified in the early 1980’s prior to gene 
expression profiling (Moll, Franke et al. 1982). The basal-like breast subtype is still today one of 
the least well understood mechanistically, it is associated with high risk for metastasis and very 
poor prognosis (Sorlie, Perou et al. 2001, Sorlie 2004).  The basal-like subtype of breast cancer 
(BBC) has the name ‘basal-like’ due to its expression of high levels of cytokeratin (CK) proteins 
(typically CK5, 6, 14 and 17)  found in the basal compartment of mammary epithelial cells in the 
normal mammary duct.   
 
The basal-like subtype has the highest rate of TP53 mutations, reaching over 80% of the tumors 
with some type of p53 mutation (Sorlie, Perou et al. 2001).  Interestingly, BBC has different 
types of TP53 mutations than the other subtypes of BC – BBC generally has non-sense and 
frame-shit TP53 mutations whereas  the luminal A and B subtypes carry missense mutations 
(Cancer Genome Atlas 2012).  BBC tumors also generally have a poorer outcome and prognosis 
(Sorlie, Perou et al. 2001, Sorlie, Tibshirani et al. 2003). BBC tumors display other markers such 
as loss of PTEN protein, overexpression of EGFR, MYC focal gain (40%) and mutations in 
BRCA1/2 (30%), PIK3CA (7%), RB (20%) and INPP4B (30%) (Foulkes 2004, Nielsen, Hsu et 
  
19 
al. 2004, Cancer Genome Atlas 2012).  BBC tumors that contain a germline BRCA1 mutation 
classify within the basal-like subtype (Sorlie, Tibshirani et al. 2003),  suggesting that lesions in 
the BRCA1 gene may be one of the first genetic hits to regulate basal-like tumorigenesis in stem 
cells (Foulkes 2004).  Basal-like breast cancer is also sometimes termed ‘triple negative’ for 
lacking estrogen receptor, progesterone receptor, and lacking HER2 ( ‘ER-/PgR-/ERBB2- 





By gene expression profiling, ERBB2 group is correlated with amplification of the receptor itself 
as well as with high expression of genes in the ERBB2 amplicon that includes GRB7, aside from 
ERBB2 receptor itself (Perou, Sorlie et al. 2000, Sorlie, Perou et al. 2001, Sorlie, Tibshirani et al. 
2003). ERBB2/HER2+ breast tumors are classified generally as ER- (Sorlie, Tibshirani et al. 
2003).  TP53 is mutated in approximately 72% of the cases, while PIK3CA is mutated about 
39%, thus expressing ERBB2 renders this a very poor outcome group (Sorlie, Perou et al. 2001, 
















BREAST CANCER MODELS 
 
 
Cell Line Models 
 
Transformation Models in MCF10A cells 
 
Multiple in vitro cancer models using MCF10A cell lines have been proposed that illustrate the 
diversity of the genetic modifications required for non-malignant cells to become transformed. 
Interestingly, loss of PTEN alone has been investigated comprehensively, such as the case in 
MCF10A cells deleted for PTEN in either one or two alleles and showed that PTEN loss causes 
enhanced growth in the absence of growth factors, resistance to anoikis and oncogenic signaling 
(Vitolo et al, 2009).   
 
A knock-in mutant EGFR (delE746-A750) in MCF10A cells has shown that EGFR alone 
increases total EGFR and phosphorylated EGFR levels in the lack of EGF (Nicolantonio FD et 
al, 2008).  Two important downstream signaling molecules of EGFR and PTEN have been 
studied in MCF10A cells -- serine/threonine kinase Akt/PKB and 3-phosphoinositide-dependent 
kinase 1 (PDK1).  Over-expressing Akt showed enhanced proliferation and disruption of 
mammary acinar architecture in MCF10A cells (Debnath J et al, 2003) whereas overexpressing 
PDK1 showed increased Akt signaling and enhanced migration, as shown (Maurer M et al, 
2009).   We demonstrated that only when PDK1 was co-expressed with a potent oncogene, NeuT 
(rat c-neu with single point activating mutation), did MCF10A cells also show higher migration, 




Deletion of the tumor suppressor p53 have shown to cause chromosomal instability and altered 
response to therapies in MCF10A cells (Weiss MB et al, 2010), whereas mutant p53 expression 
in MCF10A was shown to promote invasion, loss of directionality of migration and increased 
EGFR trafficking (Muller et al, 2009).  A more recent study showed that knocking down p53 in 
MCF10A cells altered acinus formation by leading to partial clearance of lumen cells due to 
decreased apoptosis and mutant p53 expression led to epithelial-to-mesenchymal transition 
(EMT) in MCF10A cells, as reported by previous groups (Zhang Y et al, 2011). Taken together, 
previous cell line models studying the transforming effect elicited by PTEN, EGFR and p53 in 
MCF10A cells have been critical for understanding each of their roles in cancer progression.   
 
 
Transformation Models in Hmec-hTERT cells 
 
Multiple in vitro cancer models using Hmec-hTERT (non-transformed human mammary 
epithelial) cell lines have been proposed and studied that illustrate the diversity of the genetic 
modifications that are required for non-transformed cells to become transformed. William Hahn 
and Robert Weinberg pioneered methods to transform HMEC cells (human mammary epithelial 
cells) into transformed cells by expressing a combination of viral and mammalian proteins (Hahn 
WC et al, 1999). The tumorigenesis in this particular model was mediated by the following 
collection of alterations: large T antigen (it that binds and inactivates RB and p53), small T 
antigen (it inhibits protein phosphatase 2A leading to increase level of important phosphorylated 
targets such as MEK and MAPK (Gretarsdottier, S et al., 1998)), hTERT (it contributes to the 
oncogenic state by allowing cells to divide indefinitely) and activated h-Ras
G12V
 (it induces 
strong signaling for cell survival, angiogenesis, proliferation in the absence of growth factors, 




Since the seminal work by Hahn and Weinberg, a number of other studies have sought out for 
the mammalian genes that could function in the same pathways and thus be able to substitute for 
the viral oncoproteins that are not normally expressed in human breast cancer. It was soon 
established that phosphatidylinositol 3’-kinase (PI3K) was the major target of SV40 t-Ag in the 
transformation of HMEC cells. The oncoproteins sufficient to transform human mammary cells 
in this model were hTERT, elevated myc levels, SV40 T-Ag, activated alleles of p110  in 
HMEC cells (Zhao JJ et al, 2003). Their transformation model was subsequently improved by 
excluding the need to express any viral proteins.  They were able to create a human epithelial 
transformation system that was more physiologically relevant to the human disease. High-
passaged HMEC cells that had lost p16 expression and exogenously expressed dominant 
negative p53 were able to bypass the need for SV40 T-Ag.  Additionally, expression of h-
Ras
G12V
 was crucial for the tumor formation aspect of their model (Elenbaas et al, 2001; Zhao JJ 
et al, 2003).   
 
In 2005, Kendall’s group also demonstrated that they could transform HMEC cells with the 
exogenous over-expression of only mammalian oncoproteins (hTERT, p53
DD
 (truncated mutant 




(stabilized mutant form) and h-Ras
G12V
). 
Indeed, multiple studies were able to show that it is possible to transform human mammary 
epithelial cells by targeting components of the pathways that were affected in Hahn and 









The tumor suppressor PTEN, phosphatase and tensin homolog deleted on chromosome 10, was 
first identified by the Parsons group in 1997 by deletion mapping of brain, breast and prostate 
cancer and since then PTEN has since been shown to be one of the most frequently altered genes 
in human cancers (Li, Yen et al. 1997).  In the same year, an independent group also showed that 
PTEN was lost in multiple advanced cancers (Steck, Pershouse et al. 1997) (see Figure 2.1).   
 
Specifically, PTEN was discovered at the 10q23 locus via mapping of homozygous mutations in 
chromosome 10.  In sporadic cancers, such as glioblastoma, and prostate cancer, endometrial 
carcinoma, the frequency of mono-allelic mutations at this locus has been estimated to be 
between 50 to 80 percent in sporadic tumors, and between 30 to 50 percent in breast, colon, and 
lung tumors (Salmena, Carracedo et al. 2008).  Complete PTEN loss is generally associated with 
advanced cancers and metastasis (Alimov, Li et al. 1999).  
 
Shortly after mutations in PTEN were found in variety of cancers, the Parsons group also showed 
that there was also a link of germline PTEN mutations to the cancer predisposition Cowden 
syndrome (Liaw, Marsh et al. 1997), an autosomal dominant multiple hamartoma condition that 
increases the risk of acquiring some forms of cancer including breast, and other proliferative 
diseases (Hobert and Eng 2009) (Figure 2.1).  The term PHTS, standing for PTEN hamartoma 
tumor syndrome, now unifies these clinical syndromes into one class.  Because PTEN loss seems 
to drive many of the phenotypic features of PHTS, patients with this syndrome are considered an 
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ideal population to study the biology of PTEN. Furthermore, as a common feature of most 
tumors, sporadic tumors with somatic PTEN alterations also carry other genetic alterations, 
making it more difficult to isolate the role of PTEN in tumor settings (Hollander, Blumenthal et 
al. 2011).   
 
PTEN is a phosphatase whose principal catalytic function is to de-phosphorylate 
phosphatidylinositol-3,4,5-trisphosphate (PIP3), a second messenger in the cell that is a potent 
activator of 3-phosphoinositide-dependent kinase (PDK) and AKT (Maehama and Dixon 1998).  
In tumors or syndromes displaying loss of PTEN function, the consequence is increased pool of 
PIP3 in the cytoplasm, which leads to a potent de-repression of the PTEN--phosphoinositide 3-
kinase (PI3K)—AKT pathway that in turn stimulates survival and growth (Stambolic, Suzuki et 





Figure 2.1.  Timeline of some major findings related to PTEN research since its discovery.   
The tumor suppressor PTEN was discovered to be missing at 10q23 locus, one which is highly susceptible 
to mutations by two independent groups, including the Parsons group (Li et al, 1997) and the Steck group 
(Steck et al, 1997). Since then, PTEN has been extensively studied and its importance has been illustrated 
to affect so many aspects of tumor biology. Adapted from Song et al, 2012.  
 
STRUCTURE OF PTEN 
 
 
The PTEN gene spans 105 kb and includes nine exons on chromosome 10q23.  PTEN is a 
phosphatase that can act on both phosphoinositide substrates as well as polypeptide ones.  PTEN 
can de-phosphorylate highly acid substrates on Ser-, Tyr- and Thr-phosphorylated peptides in 
vitro (Myers, Stolarov et al. 1997). The phosphatase domain of PTEN is homologous in 
sequence to those of other dual specificity protein phosphatases (DUSPs), including cell division 
cycle 14, baculovirus phosphatase, DUSP2 (PAC1), DUSP3 (VHR), and DUSP4 (MKP2) (Li, 
Yen et al. 1997, Steck, Pershouse et al. 1997). PTEN contains a catalytic signature motif, 
HCXXGXXR (where X is any a.a.), that is characteristic of other active sites of other protein 
tyrosine phosphatases (PTP) (Denu, Stuckey et al. 1996). The first 190 amino acids of PTEN in 
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the amino-terminal end of the protein, encompassing the catalytic domain motif, has homology 
to proteins such as actin-binding protein tensin1 (TNS1) and auxilin (cofactor of ATPase heat 
shock cognate 70), unlike other PTPs that would have homology to the proteins related to its 
catalytic activity (Li, Yen et al. 1997, Steck, Pershouse et al. 1997).  
 
The PTEN protein consists of a total of 403 amino acids (a.a.) and five functional domains 
(Figure 2.2).  The domains of PTEN are the PBD domain (phosphatidylinositol-4,5-bisphosphate 
binding domain), a phosphatase domain, a C2 domain (targets proteins to cell membranes), a 
carboxy-terminal tail and a PDZ-binding domain (protein-interacting domain in scaffolding 
proteins).  More specifically, in 1999, crystallographic analysis of a portion of PTEN spanning 
from residues 7 to 353 provided detailed information into how PTEN folds three dimensionally 
(Lee, Yang et al. 1999). The amino-terminal end of PTEN contains a short PtdIns (4,5)-binding 
domain (PBD).   
 
 
Figure 2.2. Structure of the tumor suppressor PTEN.   
PTEN, phosphatase and tensin homolog deleted on chromosome 10, is made up of 403 amino acids 
containing five functional domains.  The domains are an N-terminus PBD domain (phosphatidylinositol-
4,5-bisphosphate binding domain), a phosphatase domain, a C2 domain, a carboxy-terminal tail and a 





Furthermore, the HCKAGKGR catalytic signature motif in PTEN is located at the bottom of the 
pocket of the active site of the enzyme and forms the phosphate-binding loop that is comprised 
of residues 123 to 130.  The phosphatase domain of PTEN has a central five-stranded -sheet, 
grouping four -helices on one side and two -helices on an opposite side. The substrate-binding 
pocket in PTEN is deep and contains a positive charge, which is important for binding to 
phosphoinositide substrates. This is an important area for PTEN phosphatase activity as observed 
by high frequency of cancer-associated mutations that can lead to the reduction of phosphatase 
activity by PTEN (Maehama and Dixon 1998, Stambolic, Suzuki et al. 1998).   
 
Additionally, the most carboxy-terminal 170 amino acids of PTEN consists of a -sandwich 
containing two anti-parallel -sheets with two short -helices intervening between the strands 
(Lee, Yang et al. 1999).  In vitro, the C2 domain of PTEN can bind to phospholipid membranes 
and it has been shown to enable PTEN to inhibit cell migration (Lee, Yang et al. 1999, 
Raftopoulou, Etienne-Manneville et al. 2004). This structure is similar to C2 domains of 
phospho-lipase C1, protein kinase C, and PLA2 (Lee, Yang et al. 1999).  Lastly, PTEN contains 
a C-terminal tail containing PEST sequences (Pro, Glu, Ser, Thr) as well as a PDZ-domain 





PTEN is one of the most important known tumor suppressor genes for its unique PIP3 
phosphatase activity. PTEN is an essential part of the AKT pathway by inhibiting the activation 
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of AKT and its plethora of downstream target proteins that control a variety of important 
functions to maintain proper cell growth, cell cycle progression, proliferation and escape from 
apoptosis (Figure 2.3).  Specifically, when growth factors bind to receptor tyrosine kinases 
(RTKs; such as EGFR and Her2 in breast cancer) on the surface of a cell’s lipid bilayer, they 
activate them, leading to the creating of PIP3 second messengers by PI3K enzyme (Hollander, 
Blumenthal et al. 2011).  PTEN is critically important to attenuate RTK signaling toward 
activation of the AKT pathway by antagonizing the action of PI3K enzyme to decrease the pool 
of PIP3. PTEN can de-phosphorylate PIP3 to PIP2, with specific affinity for the phosphate group 
at the D3 position of the inositol ring in vitro (Maehama and Dixon 1998). The increased level of 
PIP3 at the plasma membrane not only recruits, but also allows for the activation of a group of 
proteins containing pleckstrin homology domains (PH domains) that are capable of binding 
phosphatidylinositol lipids on the cell membrane.  Namely, the PH-containing proteins recruited 
to the cell membrane are AKT family members and PDK1.    
 
AKT is activated, once brought to the plasma membrane by increased PIP3 pool, by 
phosphorylation on two specific residues, serine 473 and threonine 308.  Ser473 is 
phosphorylated by the mammalian target of rapamycin complex 2 (mTORC2) that itself is 
composed of mTOR, rapamycin insensitive companion of mTOR (RICTOR), DEP domain-
containing mTOR-interacting protein (DEPTOR), stress-activated MAP kinase –interacting 
protein 1 (mSIN1), mammalian lethal with SEC13 protein 8 (mLST8), and pro-rich protein 5 
(PRR5) (Zoncu, Efeyan et al. 2011). On its other important residue, AKT is activated by PDK1 
on Thr308 (Manning and Cantley 2007).  Once AKT is activated, out of which there are three 
different isoforms (AKT1, AKT2, and AKT3), it phosphorylates downstream signaling proteins 
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such as glycogen synthase kinase 3 (GSK3  and GSK3 ), B cell lymphoma 2 (BCL-2) 
antagonist of cell death (BAD), members of the forkhead transcription family (FOXO1, FOXO3 
and FOXO4), p21 (encoded by CDKN1A), p27 (encoded by CDKN1B), caspase 9 and the E3 
ubiquitin –protein ligase MDM2, apoptosis signaling regulating kinase 1 (MAP3K5), and PAWR 
(WT1 regulator) to drive cellular proliferation, cell cycle progression, cell survival (via inhibition 
of apoptosis), metabolism and migration (Manning and Cantley 2007).   
 
Furthermore, when AKT is activated, it can also inhibit some of its downstream targets. For 
instance, by direct phosphorylation, AKT inhibits the tuberous sclerosis protein 2 (TSC2 or also 
known as tuberin) component of the complex composed of TSC2 with TSC1.  Upon 
phosphorylation of TSC2 by AKT on specific residues, including Ser939, Ser981 and Thr1462, 
the inhibition of RAS-related small GTPase RAS homologue enriched in brain (RHEB) is lost. 
When RHEB is no longer inhibited, it activates the phosphotransferase activity of mTOR 
(Guertin and Sabatini 2007).   
 
Another protein inhibited by AKT is PRAS40 (40-kDa pro-rich AKT1 substrate 1 or also known 
as AKT1S1).  AKT inhibits PRAS40 by phosphorylation, and the resulting effect is activation of 
another important complex in the AKT pathway, mTORC1 (Vander Haar, Lee et al. 2007, 
Zoncu, Efeyan et al. 2011). mTORC1 is composed of mTOR, mLST8, DEPTOR, regulatory 
associated protein for mTOR (RAPTOR), and PRAS40, which negatively regulates mTORC1 
(Song, Salmena et al. 2012).  Once mTORC1 is activated via inhibition of PRAS40 by AKT, 
active mTORC1 phosphorylates has two main targets to active protein synthesis and translation: 
p70 ribosomal protein S6 kinase (S6K) and the eukaryotic initiation factor 4E-binding protein 1 
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(4EBP1) (Ma and Blenis 2009).  The inactivation of 4EBP1, a key negative regulator of 
proliferation downstream of mTORC1, may directly lead to cancer by promoting growth of 
sporadic cancers.  (Dowling, Topisirovic et al. 2010, Hsieh, Costa et al. 2010, She, Halilovic et 
al. 2010). Therefore, as a consequence of PTEN inactivation in the cell, mTORC1 is activated 
and the result is translation of specific mRNAs that are important for cell proliferation and 
growth. 
 
Interestingly, activation of mTORC1 signaling can trigger a negative feedback loop to inhibit the 
PTEN-PI3K-AKT pathway and thus limit tumorigenesis (Figure 2.3). The mechanism for this 
observation is that activated mTORC1 –S6K1 signaling in turn triggers a negative feedback loop 
of the insulin-PI3K-AKT pathway caused by phosphorylation and thus degradation of the insulin 
receptor substrate 1 (IRS1) (Harrington, Findlay et al. 2004, Um, Frigerio et al. 2004). If the 
mTORC1 complex is inhibited, then a hyperactive IRS1-PI3K-AKT pathway results that 
increases signaling towards the RAS-mitogen-activated-protein kinase (MAPK) pathway 
(Carracedo, Ma et al. 2008, Kinkade, Castillo-Martin et al. 2008). However, PTEN inactivation 
can override the negative feedback loop of the PI3K-AKT pathway that is mediated by 
mTORC1, the result of which is the activation of the PI3K-AKT pathway.  This has been 
demonstrated by work done in Pten+/-Tsc2+/- and Pten+/- mice overexpressing RHEB 
(Manning, Logsdon et al. 2005, Nardella, Chen et al. 2008).  Therefore, the feedback inhibition 
of the PI3K signaling pathway by PI3K independent mTORC1 activation that can be mediated 
by loss-of-function of the inhibitor of mTORC1, the TSC1-TSC2 complex, or by the gain-of-
function of RHEB that can constitutively activate mTORC1 (Manning, Logsdon et al. 2005, 






Figure 2.3.  An illustration of the canonical PTEN-PI3K pathway in the cell.   
PTEN is a central inhibitor of the PI3K (phosphoinositide-3-phosphate) pathway that signals down to 
AKT and mTOR to control many essential functions for maintaining proper cell signaling including 
proliferation, cell cycle, apoptosis, protein synthesis and metabolism.  Specifically, under physiological 
conditions, after ligand activation of a protein tyrosine kinase receptor (such as Her2 or EGFR in 
mammary epithelial cells) on the cell surface, PTEN can oppose the action of the PI3K enzyme, thus 
antagonizing the action of AKT.  However, when PTEN is lost in cancers, downstream targets of AKT 
and mTOR are activated that are important for tumor cell growth and survival.  Adapted from Hollander 






PTEN BIOLOGY AND ROLES 
 
 
Due to the importance of PTEN and its role in the cell, as well as the high incidence of functional 
disruption of PTEN in a variety of cancers, the last ten years has witnessed a major focus in 
deciphering details on classical and novel roles for this tumor suppressor inhibitor of the PI3K-
AKT pathway.  PTEN antagonizes the function of PI3K enzyme that produces PIP3 from PIP2; 
thus if PTEN is lost, excessive PIP3 second messengers accumulate.  The consequence of an 
increased PIP3 pool on the plasma membrane is the hyper activation of AKT members that can 
lead to cell survival and cell (Manning and Cantley 2007, Salmena, Carracedo et al. 2008). The 
various cellular functions of PTEN that demonstrates both its novel and conventional roles in the 
cell are described below in further detail. 
 
PTEN: Cell Motility and Polarity 
 
 
PTEN has been known to have conserved roles in cell polarity in a variety of cell types and 
species (including neutrophils, neurons, and Dictyostelium discoideium) (Liliental, Moon et al. 
2000). PTEN-PI3K pathway is known to drive membrane ruffling, cell spreading and cell 
motility via key downstream effectors such as RAC1, RHO, and CDC42 (Liliental, Moon et al. 
2000).   
 
PTEN is localized to the apical plasma membrane during epithelial morphogenesis where it 
catalyzes the conversion of PIP3 to PIP2, whereby de-activating the PI3K-AKT pathway. To 
establish and promote polarity in the cell, PIP2 recruits annexin2 (ANXA2), that in turn, brings 
CDC42 to the apical plasma membrane to bind to the partitioning defective 6 (PAR6) – atypical 
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PKC ( PKC) complex (Martin-Belmonte, Gassama et al. 2007).  PTEN may also inhibit cell 
migration of glioma cells independently of its phosphatase activity (Raftopoulou, Etienne-
Manneville et al. 2004).  
 
Losing PTEN can result in the loss of normal development of the apical surface and lumen, 
which suggests that aberrant PTEN-PI3K pathway activation might lead to a phenotype known 
as epithelial-mesenchymal transition (EMT).  Loss of regulation of the PTEN-PI3K pathway 
may induce EMT due to the following consequences: (1) loss of epithelial characteristics, (2) 
higher chances of cells acquiring instead mesenchymal characteristics, (3) increased cell 
motility, and (4) invasiveness (Song, Li et al. 2009).  Therefore, PTEN has been shown to play 
important roles in both cell motility and polarity; situations where the PI3K is hyperactive due to 
functional loss of PTEN, cells can suffer dire consequences, eventually leading to cancer. 
 
PTEN: Cellular Senescence  
 
 
Cellular senescence is defined as a cellular program that can trigger irreversible growth arrest 
and a limited replicative lifespan of primary cells (Hayflick 1965).  This safety net program is 
triggered when cells are exposed to acute stresses such as the activation and expression of 
oncogenes (this type of senescence is particularly known as oncogene-induced senescence), or 
the loss of tumor suppressor genes, such as PTEN (other examples shown are retinoblastoma 1, 
RB1, or neurofibromin, NF1) (Song, Salmena et al. 2012).  Complete PTEN loss is not frequently 
present in cancer due to its potential to drive senescence, which is not a desirable effect for the 




PTEN loss can drive senescence depending on the other genetic alterations may be found in the 
cell.  For instance, PTEN loss along with inhibition of the S phase kinase-associated protein 2 
(SKP2) has been shown to drive cellular senescence in p53- and p19
ARF
- independent fashion 
(Lin, Chen et al. 2010).  In contrast, concomitant inactivation of PTEN and transforming growth 
factor  (TGF ) – bone morphogenetic protein (BMP) – SMAD4 signaling can bypass PTEN-
loss induced senescence to allow prostate cancer cells to proliferate and metastasize in vivo 
(Ding, Wu et al. 2011). 
 
There is a dosage balance for PTEN in how it affects proliferation and cellular growth.  While 
reduced levels of PTEN can increase these two cellular functions to allow cells to divide, the 
consequence of complete loss of PTEN can be cellular senescence, a phenomenon that is 
triggered to avoid tumorigenesis due to deregulated PI3K-AKT pathway activation (Salmena, 
Carracedo et al. 2008).  However, this may be in contrast to oncogene-induced senescence where 
the cellular response may also trigger classic DNA damage response or hyper proliferation 
(Alimonti, Nardella et al. 2010).   
 
Interestingly, the tumor suppressor p53 plays an important role in senescence but is regulated 
differently depending if it is oncogene-induced senescence or PTEN-loss induced cellular 
senescence.  For example, PTEN loss in the early stages of tumorigenesis is associated with slow 
growth, cellular senescence and increased levels of p53, until p53 is concomitantly lost (Jiang, 
Chen et al. 2010).  The observed p53 up-regulation, in a PTEN-loss setting, has been shown to 
be primarily mediated through translational mechanisms that are controlled by mTORC1 (Chen, 
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Trotman et al. 2005, Nardella, Carracedo et al. 2009).  In contrast, p53 is up-regulated in 
oncogene-induced senescence setting via protein phosphorylation and stabilization (Chen, 
Trotman et al. 2005).  These findings provide a rationale as for why concomitant PTEN and p53 
functional losses are common in late-stage cancers.  
 
PTEN: Tumor Microenvironment  
 
PTEN has been shown to be involved and have a significant role in the tumor microenvironment 
(Trimboli, Cantemir-Stone et al. 2009). The focus for studying stromal fibroblasts in cancer 
initiation and progression is due to its ability to shape the architecture of the microenvironment 
to influence tumor growth (Kalluri and Zeisberg 2006).  The fibroblasts in the stroma have many 
functions that are important for tumorigenesis.  For instance, they are responsible for 
synthesizing the enzymes that control extracellular matrix (ECM) as well as for components that 
add to the structural aspects of the ECM (Kalluri and Zeisberg 2006).  Stromal fibroblasts also 
synthesize survival and growth factors, immunological chemokines and angiogenic factors 
(Kalluri and Zeisberg 2006).    
 
More specifically, when Pten was deleted in the fibroblast compartment of mammary gland 
tumors of mice, Trimboli and colleagues observed accelerated initiation, progression and 
malignant transformation of mammary epithelial tumors by the generation of a tumor permissive 
stroma (Trimboli, Cantemir-Stone et al. 2009).  It was later demonstrated that Pten loss in the 
mammary stromal fibroblasts might lead to the orchestration of transcription reprogramming of 
other cells that are found in the microenvironment (Bronisz, Godlewski et al. 2012). As a result 
of an activated oncogenic secretome in the Pten-deficient stromal cells of the tumor in the 
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mammary gland, both the AKT and Jun N-terminal kinase (JNK) pathways were activated in 
both the fibroblasts and adjacent ductal epithelium (Bronisz, Godlewski et al. 2012). 
 
The effect of PTEN in the microenvironment is also observed when analyzing human breast 
cancer samples.  Two different groups have shown that both PTEN and TP53 (encoding for p53) 
acquire genetic and epigenetic changes when analyzing the stromal fibroblasts in the tumor 
microenvironment (Kurose, Gilley et al. 2002, Hu, Yao et al. 2005).  Therefore, there is an 
increasing amount of data indicating PTEN’s important role in regulating the microenvironment. 
 
PTEN: Metabolism  
 
 
Altered metabolic function is a feature of cancer cells. In non-proliferating (differentiated) cells, 
the mitochondrial oxidative phosphorylation process (aerobic glycolysis) is favored as a source 
to generate energy (ATP) for the cell.  However, in highly proliferating cells, including cells that 
have become transformed, the preferred mechanism to obtain energy is through anaerobic 
glycolysis that converts glucose to lactate regardless of the presence of oxygen, or else known as 
the Warburg Effect (Warburg 1956). The PTEN-PI3K-AKT pathway plays an important role in 
regulating glucose metabolism in the cell since it lies downstream of the insulin receptor (INSR) 
and the IRS adaptor molecules. Thus, the PTEN-PI3K-AKT pathway, along with the 
transcriptional factor MYC and hypoxia-inducible factor 1 (HIF1), can influence critical 
metabolic pathways during proliferation and cancer.    
 
How does the PTEN-PI3K-AKT pathway mediate changes in metabolism? One possibility is by 
having this pathway inhibit GSK3, which leads to the activation of key lipogenic transcription 
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factor sterol-regulatory protein-binding protein 1C (SRTBP1C) (Horie, Suzuki et al. 2004).  
Furthermore, PTEN loss induces (1) transcription of genes involved in lipogenesis and -
oxidation by SRTBP1C and peroxisome proliferator-activated receptor  (PPAR ) and (2) 
transformation of hepatocytes that is adipogenic-like in nature (Horie, Suzuki et al. 2004).    
 
Another possibility of how PTEN-PI3K-AKT pathway affects metabolic processes is by having 
PI3K-AKT inhibit RAB-GTPase-activating protein (GAP) AS160 and thus enhance insulin-
mediated glucose uptake and membrane translocation of the glucose transporter GLUT4 (Eguez, 
Lee et al. 2005).  Moreover, PI3K-AKT signaling blocks FOXO and PPAR  co-activator 1  
(PGC1 ) in order to inhibit gluconeogenesis (Sundqvist, Bengoechea-Alonso et al. 2005, Li, 
Monks et al. 2007).   
 
Furthermore, another consequence of the PTEN-PI3K-AKT pathway in metabolism is via PTEN 
loss that can result in the activation of the PI3K-AKT pathway to promote protein glycosylation 
and folding in the endoplasmic reticulum through ectonucleotide triphosphate 
diphosphohydrolase 5 (ENTPD5), increases ATP consumption and favors the Warbug Effect 
(Fang, Shen et al. 2010).   Therefore, in tumors where PTEN is lost, or PIK3CA is mutated, there 
is resistance to the beneficiary effects of dietary restriction, which can be mimicked by over-







PTEN: Nucleus  
 
 
PTEN is known to be located at the cytoplasmic compartment of the cell; however, an increasing 
body of evidence has documented PTEN to also be found in the nucleus.  The second messenger 
PIP3 that is catalyzed back to PIP2 by PTEN is sensitive to PTEN in the cytoplasm but not in the 
nucleus, thus suggesting that nuclear PTEN might have roles other than those involving its lipid 
phosphatase activity (Lindsay, McCoull et al. 2006).  Interestingly, more aggressive cancers 
seem to be associated with loss of nuclear PTEN (Song, Salmena et al. 2012).   
 
Nuclear PTEN seems to be important in controlling both cell cycle progression and genomic 
instability. The Parsons group elegantly showed that loss of PTEN triggers phosphorylation and 
cytoplasmic sequestration of the cell cycle regulator checkpoint kinase 1 Chk1 that is mediated 
by AKT, thus disrupting the G2-M cycle checkpoint and promoting genomic instability-induced 
double strand break (DSB) in transformed cells (Puc, Keniry et al. 2005).  Furthermore, it has 
been shown that the nuclear pool of PTEN can up-regulate RAD51 (Shen, Balajee et al. 2007).  
Shen et al showed that PTEN, independently of its phosphatase activity, can positively affect 
DNA repair by regulating this important key protein involved in the double-strand break repair 
system.    
 
PTEN: Stem Cell Maintenance   
 
 
The first line of evidence indicating that PTEN is involved in stem cell homeostasis came from 
the work in 2001 by three groups independently studying Pten loss in murine neuronal tissues 
(Backman, Stambolic et al. 2001, Groszer, Erickson et al. 2001, Kwon, Zhu et al. 2001).  Three 
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different mouse models showed that Pten deletion from mouse brain led to enlarged brains, also 
known as macrocephaly, aside from disturbed pattern of brain structures.  Pten loss increased the 
total number of neurons in the fetal brain in ex vivo experiments and increased the number of 
neuronal stem cells that were able to grow in tissue culture experiments.  They also showed that 
Pten loss did not neuronal cell fate.  A few years later, Groszer et al showed that increased 
neurons and neuronal stem cells in cells lacking Pten were a consequence of the following 
factors: (1) enhanced self-renewal capacity; (2) increased G0-G1 cell cycle entry; (3) decreased 
growth factor dependency of Pten null neural/stem cell progenitors (Groszer, Erickson et al. 
2006).  By contrast, however, a study in the adult mouse dentate gyrus of Pten deleted in 
individual, quiescent radial glia-like precursors (RGLs) showed reduced, rather than expanded, 
overall RGLs pool of cells (Bonaguidi, Wheeler et al. 2011). Therefore, the discrepancies 
between these studies suggest that Pten loss in stem cells may be lineage-dependent (Song, 
Salmena et al. 2012). 
 
Later on, two groups independently demonstrated that PTEN also has a role in maintaining the 
hematopoietic stem cell (HSC) niche (Yilmaz, Valdez et al. 2006, Zhang, Grindley et al. 2006).  
They showed that conditional loss of Pten in the mouse hematopoietic system led to the 
depletion of normal HSCs while promoting excessive proliferation of leukemogenic stem cells 
(or leukemia-initiating cells), all of which led to the onset of the development of 
myeloproliferative disorders, including leukemia.  Yilmaz and colleagues further showed that 
after treating Pten-deficient cells as well as mice with the drug rapamycin (mTOR inhibitor), 
growth of the leukemogenic stem cells was effectively blocked and restored the normal self-
renewal capacity of HSCs (Yilmaz, Valdez et al. 2006).  This study highlighted the importance 
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of mTORC1 in mediating this process and the potential impact of targeting the PTEN-PI3K 
pathway to treat stem cell disorders from leukemogenic origins.  The results from these groups 
are in agreement with a model where the loss of PTEN and thus the hyper-activation of mTOR 
signaling can deplete stem cells through checkpoints that induce either cellular senescence or 




 are in place to bypass the aforementioned 
restrictions (Ito, Bernardi et al. 2009, Lee, Nakada et al. 2010).  
 
 
ALTERATIONS IN CANCER 
 
 
PTEN: Breast Cancer  
 
 
Interestingly, breast cancer is one of the few cancers that is affected by loss of PTEN expression 
that is not explained by mutations at the level of the gene.  In fact, it is very rare to find 
mutations in the gene of PTEN (<5%) in breast tumors, which instead show loss of the protein as 
shown by immunohistochemistry (Saal, Gruvberger-Saal et al. 2008).  In fact, the loss of PTEN 
immunoreactivity is observed in nearly 40% of breast cancer patients, highlighting the 
importance of utilizing immunohistochemistry to detect alterations in PTEN in patients with 
breast cancer (Sangale, Prass et al. 2011).  Patients with Cowden syndrome are at a higher risk 
for breast cancer risk in their lifetime.  Specifically, women have approximately 25-50% higher 





PTEN loss has been linked to BRCA1 deficiency in breast cancer, as shown by the landmark 
study by Saal et al in 2008.  In this study, the Parsons’ group shows that heterozygous 
inactivation of Pten in mice is associated with the formation of basal-like mammary tumors.  
Furthermore, their study shows that loss of PTEN protein expression is associated with both the 
human basal-like breast tumors of sporadic and BRCA1-associated familial (hereditary) origins.  
The breakthrough of this study lies on its explanation of at least one important mechanism that 
explains the loss of PTEN protein, which the authors showed that PTEN is found re-arranged in 
various forms (intragenic chromosomal breaks, inversions, deletions, and microcopy number 
alterations) specifically in tumors where BRCA1 is lost (Saal, Gruvberger-Saal et al. 2008).  
They argue that loss of BRCA1 in the hereditary subset of basal-like breast cancers predispose 
the mammary cells to gross genetic rearrangements due to loss of double strand DNA break 
(DBR) repair that BRCA1 would normally provide when cells are exposed to DNA damage 
(Saal, Gruvberger-Saal et al. 2008). 
 
 
PTEN: All Other Cancers associated with PHTS  
 
 
PHTS, or PTEN hamartoma tumor syndrome, is a series of clinical syndromes shown to have 
PTEN loss in common.  The consequence of germline PTEN mutations in Cowden syndrome is 
the decrease or complete loss of the expression or the activity of the mutant allele.  Figure 2.3 
highlights some of the PTEN alterations observed in tumors that arise due to PHTS.  Aside from 
the aforementioned breast cancer, PHTS can lead to a variety of other cancers in the patient’s 
lifetime, including endometrial cancer, intestinal polyps, thyroid cancers and central nervous 
system cancers (Di Cristofano, Pesce et al. 1998, Podsypanina, Ellenson et al. 1999, Stambolic, 




A well-known cancer associated with PHTS is endometrial carcinoma.  The risk a patient with 
Cowden syndrome has of having this type of cancer is estimated to be 5-10% (Blumenthal and 
Dennis 2008).   In endometrial hyperplasia, which is thought to be precursor lesions indicative of 
chances of getting endometrial carcinoma, mutations in PTEN are also observed (Risinger, 
Hayes et al. 1997, Tashiro, Blazes et al. 1997, Maxwell, Risinger et al. 1998).  Out of the 
sporadic endometrial carcinomas, approximately 35-50% have PTEN mutations (Figure 2.3) 
(Hollander, Blumenthal et al. 2011).  Endometrial cancers often show short deletion or insertion 
frameshift mutations indicative of microsatellite instability.  Specifically, frameshift mutations of 
PTEN are observed in endometrial cancers that are associated with hereditary non-polyposis 
colon cancer syndrome (Zhou, Kuismanen et al. 2002). 
 
Aside from endometrial carcinomas, thyroid cancers were among the first types of tumors to be 
associated with Cowden syndrome (Lloyd and Dennis 1963).  In benign thyroid adenomas, 
including some sporadic aggressive thyroid tumors, approximately 25% of patients were 
diagnosed with PTEN loss of heterozygosity (LOH), while mutations in PTEN were found to 
occur in a smaller frequency (Dahia, Marsh et al. 1997, Halachmi, Halachmi et al. 1998).  Less 
than 10% of malignant thyroid tumors show complete loss of PTEN (Frisk, Foukakis et al. 
2002). 
 
Another type of cancer that arises in patients with Cowden syndrome is benign and malignant 
brain tumors, such as Lhermitte-Duclos that is a rare benign tumor in the cerebellum that is 
associated with high mortality (Gustafson, Zbuk et al. 2007).  Higher PTEN expression is 
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correlated with lower grade glioblastoma whereas lower PTEN expression is associated with the 
progression of the disease (Sano, Lin et al. 1999, Schmidt, Ichimura et al. 1999).  In fact, in 
patients with glioblastoma, PTEN LOH is observed in over 70% of the cases, and over 44% of 
the other remaining PTEN allele has a mutation (Li, Robinson et al. 2002).  A possible 
mechanism for LOH in PTEN in glioblastoma was shown to be though expression of 
microRNAs.  Specifically, miR26a is a microRNA that targets PTEN for degradation and has 
been shown to be up-regulated in glioblastoma (Huse, Brennan et al. 2009).   
 
PTEN MICE MODELS 
 
Since PTEN has been discovered as a tumor suppressor, mice models have been essential in 
understanding the role of PTEN in tumor suppression.  PTEN deletion alone is sufficient to cause 
tumorigenesis in multiple tissues (Di Cristofano, Pesce et al. 1998, Suzuki, de la Pompa et al. 
1998, Podsypanina, Ellenson et al. 1999, Hollander, Blumenthal et al. 2011) (Figure 2.3). These 
efforts also revealed that PTEN functions as a haploinsufficient tumor suppressor gene in some 
tissues (Di Cristofano, Kotsi et al. 1999, Di Cristofano, De Acetis et al. 2001).  A 
haploinsufficient tumor suppressor is described as a gene in which the functional loss of one of 
its two copies in a diploid organism compromises tumor suppression as the remaining copy is not 
able to provide sufficient tumor suppressive function.  Interestingly, hypomorphic Pten mouse 
models have revealed the functional consequences of subtle down-regulation of Pten levels, 






Figure 2.3. List of tissue-specific evidence for PTEN alterations in cancers.    
PTEN is altered either at the genetic and/or protein levels in cancers to promote tumorigenesis. Adapted 







The TP53 gene, residing on chromosome 17p13 and encoding the p53 protein, is the most 
frequent target for mutation in cancer, with more than half of all tumors showing mutation at its 
locus (Vogelstein, Lane et al. 2000, Petitjean, Mathe et al. 2007). TP53 was discovered in 1979 
in a complex with the simian virus (SV40) large T-antigen (Lane and Crawford 1979, Linzer and 
Levine 1979), and given the abundance of this protein found in tumor samples as opposed to 
normal tissue, p53 was first thought first to be an oncogene (DeLeo, Jay et al. 1979, Rotter 
1983).   
 
 
Figure 3.1. Main discoveries in the p53 field in the first thirty years since its discovery.   
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The tumor suppressor p53, a transcription factor, has been thoroughly studied since 1979, and shown to 
play an important role in a variety of regulations to keep the integrity of a healthy cell. Adapted from 
Levine and Oren, 2009. 
 
In fact, for the first decade after its discovery, p53 was considered a proto-oncogene (Levine and 
Oren 2009) (Figure 3.1 timeline of p53 for the last 30 years), partially due to findings that 
overexpression of p53 in p53-null cells increased tumorgenicity (Wolf, Harris et al. 1984) and 
that ectopic expression of p53 cDNAs were able to cooperate with oncogenic Ras to transform 
primary cells in culture (Eliyahu, Raz et al. 1984, Parada, Land et al. 1984).  
 
There were early experiments, however, that called into question whether p53 was indeed an 
oncogene. For instance, when murine Trp53 gene was inserted into various tumor models, the 
gene was inactivated (Wolf, Harris et al. 1984, Ben David, Prideaux et al. 1988). Eventually the 
discrepancy among findings questioning whether p53 could transform primary cells was resolved 
when the sequences of the cloned TP53 cDNAs used by the different research groups showed 
that they all differed from each other (Levine and Oren 2009). Strikingly, the early experiments 
showing the capacity of p53 to transform cells and promote in vivo tumor growth was due to a 
missense mutation found in TP53 previously isolated and cloned from tumor cells (Hinds, Finlay 
et al. 1989, Hinds, Finlay et al. 1990, Levine and Oren 2009).  Therefore, in fact, the early 
studies demonstrated the role of mutant TP53 in cancer biology.   
 
It was not until 1989 that seminal findings in the p53 field demonstrated that the product of this 
gene was not an oncogene, but instead a tumor suppressor.  The group led by Vogelstein 
demonstrated that over half of colorectal carcinomas showed loss of heterozygosity at the p53 
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locus, or mutation of one allele and loss of the other (Baker, Fearon et al. 1989). Therefore, in 
tumor specimen, p53 was behaving as a classical tumor suppressor. Work by Oren and Levine 
later fortified p53’s role as a tumor suppressor by showing that overexpression of wildtype p53 
was sufficient to repress transformation (Eliyahu, Michalovitz et al. 1989, Finlay, Hinds et al. 
1989). A mouse model for which p53 was knocked out later solidified the tumor suppressor role 
of wildtype p53 (Donehower, Harvey et al. 1992). In fact, subsequent research earned p53 the 
title:  “guardian of the genome” (Lane 1992).  
 
GENE AND PROTEIN 
 
The TP53 gene belongs to a highly conserved gene family containing two additional members – 
p63 (Schmale and Bamberger 1997) and p73 (Kaghad, Bonnet et al. 1997). The structurally and 
functionally related members, p63 and p73, have roles in normal development of tissue whereas 
p53 has evolved a tumor suppressor role in higher organisms (Irwin and Kaelin 2001). TP53 
encompasses a 20-Kb gene made up of 11 exons and 10 introns, encoding a protein with 53 kDa 
in molecular weight (Lamb and Crawford 1986). 
 
The wildtype p53 protein has 393 amino acids and is composed of multiple structural and 
functional domains (Figure 3.2) (Bai L 2006). The N-terminus of the protein contains an amino-
terminal domain, the transactivation domain (spanning amino acid residues 1-42 and now 
recognized to be two distinct transactivation domains (Laptenko and Prives 2006)) that interacts 
with various transcription factors such as MDM2 (murine double minute 2) and 
acetyltransferases (Fields and Jang 1990, Lin, Chen et al. 1994). Also part of the N-terminus 
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region of p53 is a proline-rich region domain (spanning residues 61-94) that contains multiple 
copies of the PXXP sequence, where X stands for any amino acid. This region is responsible for 
p53 stability; if this region is deleted, p53 becomes more susceptible to degradation by MDM2 
(Sakamuro, Sabbatini et al. 1997). 
 
 
Figure 3.2. p53 structural and functional domains.  
The p53 protein contains a total of 393 amino acids that make up three important functional domains, 
namely the transactivating domain in the N-terminus of the protein, the DNA-binding domain in the 
central core of p53, and finally the tetramerization domain in the C-terminus end. The N-terminus also 
contains a proline rich area that is made up of multiple PXXP residues. The DNA-binding domain is 
responsible for sequence-specific DNA binding (a target area for mutations).  The regulatory domain in 
the C-terminus contains basic residues that undergo post-translational modifications (phosphorylation and 
acetylation). A nuclear localization sequence (NLS) as well as a nuclear export signal sequence (NES) lie 
in the C-terminus. Adapted from Bai et al, 2006. 
 
 
Following the amino-terminus, the central core domain (spanning amino acids 102-292) makes 
up the DNA-binding domain (Figure 3.2).  This region of p53 is required for sequence-specific 
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DNA binding.  The consensus sequence contains two copies of a motif that is 10-bp composed of 
5’-RRRCWWGYYYn0-14RRRCWWGYYY-3’ (where (R) purine, (C) cytosine, (W) A/T,  (n) 
any nucleotide), separated by 0-14 bp (el-Deiry, Kern et al. 1992, Funk, Pak et al. 1992, Riley, 
Sontag et al. 2008).  The central core domain is the most highly conserved region of p53 (Kaelin 
1999) and it is considered a hotspot region for mutations across cancers where TP53 missense 
mutations are found mostly between residues 126-306, with particular focus on the residues 













Figure 3.3. Mutational spectrum of TP53 in human cancers.  
Schematic illustration of the TP53 missense mutations in relation to the different domains.  According to 
a pool of approximately 19,250 patients, most of the mutations in the tumor suppressor TP53 occur in the 
DNA binding domain (mutations are plotted frequency versus the amino position). The most common 
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missense mutations in the ‘hot-spot’ domain of p53 are R175, G245, R248, R249, R273 and R282.  
Adapted from Freed-Pastor and Prives, 2012. 
 
The C-terminus domain region (residues 301-393) of TP53 contains a nuclear localization 
sequence (NLS), three nuclear export signal sequences (NES), an oligomerization domain  
(residues 324-355) and a strongly basic regulatory domain (residues 363-393) (Vousden and Lu 
2002) (Figure 3.2).  The negative regulatory domain of TP53 has also been implicated in cell 
death (Chen, Ko et al. 1996). According to the allosteric model where the C-terminal region of 
p53 may regulate the ability of its core DNA binding domain to lock the latter in a latent 
conformation, post-translational modifications can disrupt this interaction and result in enhanced 
transcriptional activity by a more active DNA binding domain (Bai L 2006). 
 
PHYSIOLOGICAL FUNCTIONS OF P53 
 
The protein p53 is a tetrameric transcription factor that can hetero-oligomerize wildtype and 
mutant monomers to result in a dominant negative effect (Chene 1998, Wijnhoven, Speksnijder 
et al. 2007).  Activation of p53 can lead to an array of biological consequences in the cell, 
including induction of apoptosis, cell cycle regulation, development, differentiation, gene 
amplification, DNA recombination, and cellular senescence (Oren and Rotter 1999).  p53 
activation results in overall increase in p53 protein level as well as changes in protein through 
post-translational modifications which can also result in activation of p53 target genes (Fritsche, 
Haessler et al. 1993).  
 
Because of its pivotal importance in the cell, p53 is tightly regulated.  During normal 
homeostasis, p53 pool is low as it is degraded after MDM2-mediated ubiquitination, which tags 
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p53 for destruction (Figure 3.4) (Kruse and Gu 2009).  According to the classical mode of p53 
regulation, once p53 is activated by different sources of stresses, it is stabilized via 
phosphorylation. As for p53’s response to DNA damage leading to double-strand breaks in the 
DNA, ATM (ataxia-telangiectasia mutated) kinase is activated, which in turn activates Chk2 
kinase (Matsuoka, Huang et al. 1998).  Both ATM and Chk2 then phosphorylate p53 leading to 
p53-dependent cell cycle arrest or apoptosis (Banin, Moyal et al. 1998, Canman, Lim et al. 
1998).  Additionally, DNA damage can also lead to replication blockage that in turn activates 
ATR (ATM and Rad3-related) kinase and then Chk1, both of which phosphorylate and activate 
p53 (Tibbetts, Brumbaugh et al. 1999, Shieh, Ahn et al. 2000).  As a result of its activation via 
phosphorylation, p53 then becomes accumulated in the nucleus where it binds to specific sites in 
the regulatory regions of p53-responsive genes to promote their transcription by recruiting 
general transcriptional machinery (Kern, Kinzler et al. 1991).  
 
 
Figure 3.4. Classic model for p53 activation.   
Three steps are taken once p53 is activated via different stresses: (1) p53 is stabilized via post-
translational modification (via phosphorylation) and not  degraded by MDM2; (2) p53 translocates to the 
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nucleus where it binds to the promoter of p53-responsive genes; (3) p53 then recruits transcriptional 
machinery components for transcriptional activation. Adapted by Kruse and Gu, 2009. 
 
There are many genes shown to be transcriptional targets of the wildtype human TP53.  The gene 
targets of p53 activation, in turn, mediate a myriad of downstream cellular functions (Figure 3.4).  
For instance, p53 activation allows for: (1) cell cycle arrest that can be mediated by such genes 
as CDKN1A, MIR34A, etc.; (2) DNA repair that can be mediated by GADD45 (growth arrest and 
DNA-damage inducible protein 45), and genes of the Bcl-2 family, among other genes; (3) 
apoptosis that can be mediated by PUMA, BAX, etc.; (4) cellular senescence that can be mediated 
by CDKN1A, PA1, among others; and (5) metabolic processes that can be mediated by TIGAR, 
SCO2, GLS2, etc. (Prives and Hall 1999, Vousden and Lu 2002, Fridman and Lowe 2003, Riley, 
Sontag et al. 2008, Vousden and Prives 2009, Vousden and Ryan 2009).  The aforementioned 
cellular outcomes of p53 activation have been demonstrated to be important for p53’s tumor 
suppressive function. For instance, the tumor suppressive function of p53 has been illustrated in 
mice that carry a deletion in its proline-rich domain that were protected from tumor development 
because now they lack the ability to induce cell cycle arrest but retain the ability to induce 
programmed cell death (Toledo, Krummel et al. 2006).  
 
From the different cellular responses that p53 elicits, one of the most notable are the induction of 
cell cycle arrest and apoptosis.  p53 can also elicit cell cycle arrest in the G1, G2 and S phases of 
the cell cycle (Agarwal, Agarwal et al. 1995).  As a result of p53 mediated G1 and G2 cell cycle 
arrest, the cell has time to repair any genomic damages that it may have incurred prior to 
resuming the cell cycle to critical stages of DNA synthesis and mitosis.  Arrested cells are able to 
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proliferate again once they have repaired the damaged DNA via biochemical functions mediated 











Figure 3.5.  Downstream targets of p53 activation due to various cellular stresses.  
 p53 sits at the crossroads of stress response pathways and has effects in cell cycle checkpoints, DNA 
repair, apoptosis and senescence, where different sources of stresses, such as DNA damage, oncogene 
activation, hypoxia, or heat shock can activate the transcriptional factor p53 to induce and/or repress 
target genes. Adapted from Bai et al, 2006. 
 
Perhaps one of the best well-known targets of p53 is p21
waf1/Cip1
, a cyclin-dependent kinase 
(CDK) inhibitor.  p21
waf1/Cip1 
is a primary mediator of p53-dependent G1 cell cycle arrest 
following DNA damage (el-Deiry, Tokino et al. 1993, Harper, Adami et al. 1993, Xiong, 
Hannon et al. 1993).  When p53 is activated, in response to cellular stresses, it up-regulates the 
mRNA and the protein levels of p21
waf1/Cip1 
(el-Deiry, Tokino et al. 1993).  As a result, through 
its ZRXL motif, p21
waf1/Cip1 





induces G1 cell cycle arrest by blocking cyclin E/CDK2- mediated 
phosphorylation of RB and releasing E2F to induce genes that are required for S-phase entry 
(Chen, Ko et al. 1996). 
 
  
Figure 3.6. The two different p53 apoptotic driven pathways and their target genes.   
Apoptosis can be mediated by p53 via either the extrinsic or intrinsic pathways. The extrinsic pathway is 
mediated by the death receptor pathway and activates caspase 8 to lead to apoptosis; whereas the intrinsic 
pathway is also called the mitochondrial pathway that activates caspase 9 to lead to apoptosis. Adapted 
from Bai and Zhu, 2006. 
 
As a gatekeeper of the cell, when p53 monitors cellular stress that causes severe damage, it can 
induce apoptosis if necessary (Kinzler and Vogelstein 1997, Levine 1997).  When p53 induces 
apoptotic gene products, apoptosis may be induced through two different pathways: the extrinsic 
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or the intrinsic pathway (Figure 3.6).  The intrinsic apoptotic pathway (the mitochondrial 
pathway) is activated when cells are exposed to stress and is mediated through different Bcl-2 
family members (Korsmeyer 1999, Cory and Adams 2002), which are composed of three main 
classes: anti-apoptotic proteins (Bcl-2 and Bcl-XL), pro-apoptotic proteins (Bak, Bax and Bcl-XI) 
and pro-apoptotic “BH3-only” proteins (Bad, Bid, Noxa, and PUMA) (Haupt, Berger et al. 
2003).  In the intrinsic pathway, genes like Bax, Bid, Puma, p53AIP1 and Nova are located in the 
mitochondria and once activated, they cause loss of mitochondrial membrane potential to release 
cytochrome c, which results in the apoptosome complex with caspase 9 and Apaf-1 (Oda, Ohki 
et al. 2000, Nakano and Vousden 2001, Yu, Zhang et al. 2001, Matsuda, Yoshida et al. 2002).  
 
On the other hand, in the extrinsic pathway (the death receptor pathway) as shown by Figure 3.6, 
p53 can promote apoptosis by activating receptors on the cell surface membrane such as 
Fas/CD9, DR4 and DR5, which may inhibit IAPs (inhibitor of apoptosis proteins) (O'Connor, 
Harris et al. 2000, Takimoto and El-Deiry 2000, Liu, Yue et al. 2004). TRAIL (tumor necrosis-
factor related apoptosis-inducing ligand), Fas ligand, and chemotherapeutic agents can trigger 
apoptosis via either DR4 or DR5 (Sheikh, Burns et al. 1998, Liu, Yue et al. 2004).  In fact, in 
most tissues, Fas has been shown to be essential for p53-dependent apoptosis (O'Connor, Harris 
et al. 2000). It has been suggested that it is the intrinsic pathway that is utilized mainly in p53-
mediated apoptosis though the extrinsic pathway is used to increase the apoptotic response  
(Fridman and Lowe 2003).  
 
It is important to note that p53 activation cannot only lead to direct or indirect transcriptional 
activation but elevated p53 levels can result in repression of gene transcription as well due to p53 
being a multifunctional protein (Mack, Vartikar et al. 1993).  For instance, some of the repressed 
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p53-responsive genes are negative regulators of apoptosis, such as SURVIVIN, BCL-2, BCL-X, 
CYCLIN B1 and MAP4 (Vousden and Lu 2002). One study in ovarian cancer cells that over-
expressed p53 indicated that of all putative p53-responsive genes, 80% of them were in fact 




Mutant p53 in Breast Cancer  
 
 
Over 70% of mutations in TP53 in breast cancer are classified as missense mutations (Petitjean, 
Mathe et al. 2007). The mutational spectrum of TP53 in breast cancer is correspondent to the 
mutational pattern of p53 in other tumors as well (Walerych, Napoli et al. 2012) (Figure 3.7). For 
instance, codon 220 in p53 ranks 7
th
 most frequent missense mutation in other cancers (2%) 
while it ranks in 4
th
 place for breast cancer (3.6%) (Feki and Irminger-Finger 2004).  There is a 
favorable association between TP53 mutations and BRCA1/2 germline mutations, likely due to 
the dysfunctional DNA damage pathway (Greenblatt, Chappuis et al. 2001, Manie, Vincent-
Salomon et al. 2009).  
 
Since most hereditary TP53 mutations preferentially induce breast cancer in patients with Li-
Fraumeni syndrome (a hereditary tumor –predisposing disorder in patients carrying TP53 
mutations), this may be indicative of p53’s role as an early event in spontaneous mammary 
tumors as well (Bull, Ozcelik et al. 2004, Olivier, Langerod et al. 2006, Malkin 2011). 
Furthermore, missense mutations in TP53 are more frequent in high-grade spontaneous breast 
carcinomas, and therefore may suggest that this potentially early mutational event may be one of 
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the decisive events in the development of a high-grade versus low-grade molecular pathway 
given their early proposed divergence (Bull, Ozcelik et al. 2004, Olivier, Langerod et al. 2006, 
Wiechmann and Kuerer 2008, Bombonati and Sgroi 2011).  
 
In breast cancer, TP53 is commonly mutated and possibly one of the key driving factors in the 
triple negative/basal-like subtype of breast cancer, one of the most lethal of all subtypes 
(Walerych, Napoli et al. 2012).  The spectrum of mutants is seen mostly to occur as single amino 
acid substitutions, which for various reasons may lose the onco-suppressive function of p53 but 
in turn may acquire properties of gain of function mechanisms. The most commonly changed 
residues – R248Q and R273H – in breast cancer affect the DNA-binding properties of p53 and 
thus have been called ‘contact mutants’ (Walerych, Napoli et al. 2012).  There are also mutants 
of TP53 dubbed ‘structural mutants’, such as R175H and Y220C, which result in distorted DNA 
binding domain (DBD) structure under physiological conditions (Walerych, Napoli et al. 2012).  
 
Mechanisms of Action of Mutant p53 Molecules in Breast Cancer  
 
Transcriptional Activity Mechanism  
 
In vitro biophysical studies have suggested that TP53 mutants in the DBD domain might have a 
spectrum of how much the DBD destabilization affects the protein’s function, thus suggesting 
that DBD mutants might be proteins that are functionally different (Bullock, Henckel et al. 
2000). In another study that analyzed TP53 mutants that are frequently expressed in breast 
cancer, they showed that many of the mutants possessed an altered promoter activation spectrum 
(Jordan, Inga et al. 2010).  This example of mutant p53 molecules causing a shift of 
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transcriptional specificity of wildtype p53 rather than a full displacement of wildtype p53 targets, 
illustrates an element of mutant p53 gain-of-function (GOF).  For instance, Y220C mutant still 
transactivated the promoter of a p21 gene, WAF1, the most sensitive of wildtype p53 response 
elements, and not some other responsive elements (Jordan, Inga et al. 2010).   
 
Various studies showing that many loci lacking p53 responsive elements are direct 
transcriptional targets of hot-spot mutants p53 proteins, suggesting that mutant p53 may also 
acquire distinct DNA-binding and transactivation properties (Chicas, Molina et al. 2000, Scian, 
Stagliano et al. 2004, Weisz, Zalcenstein et al. 2004, Fontemaggi, Dell'Orso et al. 2009, Yan and 
Chen 2009).  Girardini and colleagues were able to identify 10 novel genes controlled and bound 
by R280K mutant p53 (Girardini, Napoli et al. 2011) while another study by Blandino et al 
showed that 40 promoters bound de novo by R175H mutant p53 in breast cancer cell lines 
(Dell'Orso, Fontemaggi et al. 2011).  Furthermore, mutant p53 proteins have been shown to also 
directly activate transcription of specific micro RNA species (Donzelli, Fontemaggi et al. 2012) 
as well as attenuate microRNAs processing (Suzuki, Yamagata et al. 2009).   
 
Protein Stability Mechanism 
 
 
Enhanced protein stability is another mechanism that can complement the altered transcriptional 
abilities of mutant p53 molecules by increasing the total level of p53. Under normal 
physiological conditions, p53 is destabilized by its interaction with the protein Mdm2, an E3 
ubiquitin ligase that is a direct transcriptional target of p53 (Bond, Hu et al. 2005). However, in 
tumor cells where one or two mutant alleles of TP53 are expressed, this important negative 
feedback loop is dysfunctional and can result in increased levels of mutant p53 in the cell 
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(Walerych, Napoli et al. 2012). It has been shown that mutant p53 variants can be destabilized by 
MDM2 as well as other E3 ligase enzymes via ubiquitination (Lukashchuk and Vousden 2007).   
However, in mammary tumor cells, several mechanisms may counteract this negative feedback 
loop as shown by Hsp90-mediated stabilization (Muller, Hrstka et al. 2008) or p16
INK4
 
upregulation (Zhang, Pickering et al. 2006).   
 
The importance of stability of mutant p53 is illustrated by a study by Terzian and colleagues 
showing that MDM2-/- mice crossed with mice carrying the R172H p53 knock-in mutant result 
in increased mutant p53 stability and shorter survival of the animals (Terzian, Suh et al. 2008), in 
contrast to only R172H knock-in mice (Lang, Iwakuma et al. 2004, Olive, Tuveson et al. 2004). 
Such result suggests that R175H p53 gain-of-function may be strongly dependent on p53’s 
stability (Walerych, Napoli et al. 2012). 
 
Other post-translational Modifications as Mechanism of Action 
 
 
Post-translation modifications (PTM), aside from ubiquitination, can also alter mutant p53 
stabilization and activity in breast cancer cells, although their roles have not been as extensively 
studied (Matsumoto, Furihata et al. 2006, Dai and Gu 2010).  For instance, phosphorylation of 
p53 in breast cancer tumor samples and breast cancer cell lines is detected regardless of the T53 
mutational status (Minamoto, Buschmann et al. 2001).   
 
Girardini et al showed that oncogenic stress could modify mutant p53 on the same regulatory 
sites as wildtype p53 is regulated (Girardini, Napoli et al. 2011).  Another study done in cultured 
cells showed that expression of a non-phosphorylatable variant of p53 (S392A) enhanced the 
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oncogenic potential of another variant p53 R175H, suggesting that phosphorylation at this 
residue (S392) might negatively affect the gain-of-function of the mutant p53 (Minamoto, 
Buschmann et al. 2001).  In vivo, this correlation has been suggested when Yap et al showed in 
breast tumor samples that phosphorylation at S392 was reduced in samples with high mutant p53 
level (Yap, Hsieh et al. 2004).  
 
The extent to which we know the effects of post-translational modifications (PTM) of mutant 
p53 variants is very small compared to the vast knowledge of PTMs in wildtype p53 and thus we 
still have many unknowns to understand the role of PTMs for the function of mutant p53 
molecules (Walerych, Napoli et al. 2012).  For instance, Perez et al showed that selected mutant 
p53 species can be reactivated through acetylation by PCAF (Perez, Knights et al. 2010).  
However, our knowledge of how acetylation, methylation or sumoylation of specific p53 mutants 
can affect their functions in breast cancer is still limited.  Therefore, more work in this area will 
be important as pharmacological intervention of the enzymes that control PTMs in mutant p53 
proteins can be utilized and tested as a means of anti-tumor therapy. 
  
 
MUTANT TP53 MODELS 
 
Mouse Models  
 
 
Missense mutations in p53 can confer gain-of-function of the protein, as defined by the ability of 
the aforementioned type of p53 mutation type to actively contribute to tumor progression and 
aggressiveness (Wolf, Harris et al. 1984, Halevy, Michalovitz et al. 1990, Dittmer, Pati et al. 
1993). Through gene knock-in technology, some of the most accurate mouse models to mimic 
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the TP53 missense alterations seen in patients with Li-Fraumeni have been engineered (Figure 
3.7).   
 
Two important hotspot mutants of TP53 in humans, namely R175H and R273H variants, have 
been constructed in murine models with the equivalent residues, R172H and R270H, being 
investigated (Liu, McDonnell et al. 2000, Lang, Iwakuma et al. 2004, Olive, Tuveson et al. 
2004). The spectrum of the tumors differed between p53-/- and p53+/- mice, with a higher 
metastasis frequency in the homozygous mutant mice, along with differences between the two 
different mutants (Olive, Tuveson et al. 2004).  Unlike patients with Li-Fraumeni condition, 
mice carrying the corresponding two hot spot mutants displayed low frequency of breast cancer 
(Lang, Iwakuma et al. 2004, Olive, Tuveson et al. 2004), likely due to the background of the 
mice utilized as well as to the appearance of other tumors which could mask the appearance of 
mammary carcinomas (Walerych, Napoli et al. 2012).   
 
When the single TP53 R270H allele was expressed in a mammary epithelium background, 
increased formation of breast cancer was indeed observed (Wijnhoven, Zwart et al. 2005). 
Multiple useful models of TP53 mutations have been studied (Figure 3.7) but they also carry 




Figure 3.7. Most frequent p53 missense mutations in breast cancer.  
The most common p53 mutations that occur in breast cancer and their oncogenic properties in mice 












INTRODUCTION TO EGFR/HER RECEPTORS 
 
Epidermal growth factor receptor (EGFR) was first isolated in 1980, twelve years ago, years 
after the discovery of one of its ligands, EGF in 1962 (Cohen 1962, Cohen, Carpenter et al. 1980, 
Cohen, Ushiro et al. 1982).  The role of EGFR is best known for its classical function as a 
transmembrane receptor tyrosine kinase (RTK) that is activated upon ligand binding. Since its 
discovery, there has been a plethora of publications further detailing the structure(s), different 
roles, mechanisms of action, signaling pathways, aberrations linked to pathogenesis for EGFR, 
as well as its close HER family members (HER2/c-ErbB2, ErbB3, ErbB4).  EGFR is known to 
be involved in early embryonic development, tissue renewal, repair and cancer.  Due to its 
amplification and over-expression in breast cancer, especially in the basal-like subtype (BBC), 
one of the major focuses of understanding basal-like mammary tumors is better understanding 





Gene and Protein  
 
EGFR is a member of the ErbB protein family that is composed of three other closely related 
type 1 transmembrane tyrosine kinase receptors: ErbB2 (HER2/c-neu), ErbB3 (HER3), and 
ErbB5 (HER4).  EGFR is composed of 28 different exons and the mature protein product is a 
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large l70-kDa extracellular receptor synthesized from a 1210-residue polypeptide precursor that 
is then cleaved at the N-terminal end to yield a 1186-residue protein that is inserted into the 
membrane (Cohen, Ushiro et al. 1982, Ullrich, Coussens et al. 1984).  All ErbB receptors consist 
of an extracellular domain that binds to ligands (except in the case of HER2), a transmembrane 
domain and a cytoplasmic domain comprised of a juxtamembrane domain, a tyrosine kinase 
domain and an auto-phosphorylation domain in the most C-terminus end (Figure 4.1).   
 
 
Figure 4.1. Representation of the domains of the EGFR polypeptide.   
The mature EGFR polypeptide is made out of a total of 1186 amino acids and has three main domains: 
the extracellular ligand binding domain, the juxtamembrane domain (JM) that follows the transmembrane 
domain that makes a single pass through the plasma membrane, and the carboxyl-terminal (CT) domain 
that contains kinase activity.  Within the extracellular domain, there are two ligand-binding subdomains 
(L1 and L2) as well as two cysteine-rich domains (CR1 and CR2). Adapted from Jorissen et al 2003. 
 
The ectodomain, that is glycosylated and the ligand binding domain of EGFR, consists of four 
subdomains referred to as L1, CR1 (S1), L2 and CR2 (S2) domains, or more simply as 
subdomains I, II, III, and IV, respectively (Ullrich, Coussens et al. 1984, Lax, Burgess et al. 
1988, Lax, Johnson et al. 1988) (Figure 4.1).  Of these, L1 and L2 form the ligand-binding sites 
and CR1 and CR2 are homologous cysteine-rich regions (Garrett, McKern et al. 2002, Ogiso, 
Ishitani et al. 2002).  Interestingly, the cysteine residues between the two S1/S2 domains do not 
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form disulphide bonds and it is suggested that these regions are derived from gene duplication 
(Stein and Staros 2000, Jorissen, Walker et al. 2003).  Furthermore, the EGFR signaling network 
has had a highly conserved function throughout evolution.  As can be seen in Figure 4.2, the 
primordial signaling unit in the nematode Caenorhabditis elegans (C. elegans) was composed of 
a single EGF-like ligand called LIN-3 and one receptor named LET-23.  The characteristic six 
cysteine residues forming three disulphide bonds between the ligand LIN-3 and the receptor 
LET-23 have remained conserved from C. elegans to the Drosophila to mammals.  However, 
through time, the complexity of the signaling network and the number of receptors have 
expanded to multiple ligands, as in the case of Drosophila, to multiple receptors with a complex 
combination of various ligands in mammals (Aroian, Koga et al. 1990, Hill and Sternberg 1992). 
 
Figure 4.2.  The EGFR/HER module is highly conserved through evolution.   
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Over time the EGFR signaling module has become more complex varying from a single receptor and 
ligand in C. elegans to multiple ligands in fruit fly to multiple receptors with a variety of ligands in 
mammals. Adapted from Yarden 2001. 
 
 
HER Family Members 
 
 
The four members of the HER receptor family of proteins are Her1 (EGFR), ErbB2 (Her2), 
ErbB3 and ErbB4.  The differences in the intracellular carboxy-terminal end of each family 
member gives rise to a large repertoire of signaling molecules that interact with the heterodimers, 
which can lead to an expansion of the total number of pathways that can be stimulated by one 
single ligand on the cell surface (Jorissen, Walker et al. 2003).  EGFR interacts with all three of 
its known homologues in a ligand dependent fashion to form heterodimers, though it can also 
bind to another EGFR to homodimerize (Olayioye, Neve et al. 2000, Yarden and Sliwkowski 
2001).   
 
Even though mutations in EGFR in breast cancer are very rare, with amplification accounting for 
approximately only 1%, EGFR is known to be over-expressed in breast cancer, particularly 
within the basal-like subtype (Burness, Grushko et al. 2010).  Over-expression of EGFR can 
occur in as much as 30% of breast cancers (which means that it is closer to 70% over-expression 
within the basal-like subtype) (Ro, North et al. 1988, Harris, Nicholson et al. 1989, Al-Kuraya, 
Schraml et al. 2004). EGFR over-expression has also been associated with inflammatory breast 
cancer that is characterized by loss of estrogen receptor (ER-) and an aggressive phenotype that 




The other highly relevant HER receptor family member in breast cancer is HER2, or ErbB2, that 
is not dependent on ligand binding for its activation.  Neu, HER2’s the rat homologue, was first 
identified in a chemically-induced neuroblastoma and shown to be similar to retroviral oncogene, 
v-ErbB, related to EGFR (Schechter, Stern et al. 1984).  Amplification of HER2, which occurs 
between 20-30% of BCs, is associated with poor-prognosis though it is an early genetic event 
(Schechter, Stern et al. 1984, King, Kraus et al. 1985, Slamon, Clark et al. 1987).  Due to its high 
prevalence in breast cancer, over-expression of Her2 in BC emerged as its own subtype in breast 
cancer upon gene expression profiling analysis (Sorlie 2004).  In most normal adult tissues, the 
expression of Her2 is very low or non-existent; therefore, there is a large differential expression 
of this mutant receptor in breast cancer cells, which can express up to two million Her2 receptors 
per cell (breast cancer cells can express between 25-50 copies of Her2) (Eccles 2011).   
 
Recent work by Gatza and colleagues has shown that there is not only genetic heterogeneity 
within the ErbB2+ breast tumors, but that there is significant epigenetic influence (Gatza, Kung 
et al. 2011).  If hypoxia-regulated genes were expressed at high levels, then ErbB2+ tumors 
showed characteristics closer to basal-like tumors, while the lack of this signature of hypoxic 
genes described the ErbB2+ tumors as behaving more like luminal breast cancers.   
 
In breast cancer, Her3 is over-expressed in approximately 10% of all cases (Eccles 2011).  
Because Her3 is so commonly associated with Her2, its role in breast tumorigenesis becomes 
harder to decipher.  Her3 has no intrinsic kinase activity (see Figure 4.2), and therefore it must 
heterodimerize in order for it to be phosphorylated by other receptors.  There is likely a pivotal 
role for Her3 in Her2+ human breast tumors given that there is evidence for preferential 
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phosphorylation of Her3 in the aforementioned tumors (Stern 2008).  When Her3 is activated, it 
preferentially activates the PI3K pathway – evidence for this selection is the presence of multiple 
binding sites for the p85 regulatory subunit of the PI3 kinase enzyme (Eccles 2011).  Moreover, 
some studies suggest that Her3 is associated with longer survival and ER positivity in breast 
cancer (Eccles 2011). 
 
The fourth member, though least well understood of all HER family of receptors, is the 180-kDa 
glycoprotein Her4.  This gene was originally cloned in 1993 from a human breast cancer cell line 
(MDA-MB-453) (Plowman, Culouscou et al. 1993). The full-length form of Her4 seems to have 
different functions than its splice variant that is a cleaved form of Her4 called 4ICD (Sundvall, 
Iljin et al. 2008).  There is contradictory data showing both positive and negative associations 
with prognosis in breast cancer, suggesting Her4 might act as both a tumor suppressor and an 
oncogene (Junttila, Sundvall et al. 2000, Gullick 2003).  Interestingly, up-regulation and down-
regulation of Her4 is observed in vivo in breast tumor samples (Sundvall, Iljin et al. 2008). 
Because the promoter of HER4 contains three estrogen responsive elements half sites, which can 
recruit estrogen receptor to these sites, breast cancers expressing Her4 are generally associated 
with ER+ status (Eccles 2011).  Her4 has been shown to have high affinity for the following 
ligands: HB-EGF, betacellulin, epiregulin, and neuregulins (Plowman, Green et al. 1993, Riese, 
Bermingham et al. 1996, Carraway, Weber et al. 1997, Elenius, Paul et al. 1997, Komurasaki, 
Toyoda et al. 1997, Zhang, Sliwkowski et al. 1997, Harari, Tzahar et al. 1999).   
 




The major partner of EGFR is HER2 (Tzahar, Waterman et al. 1996).  There are a variety of 
mechanisms that contribute to this preferred heterodimeric partnering that makes their signal 
particularly potent.  For instance, heterodimeric complexes containing HER2 are more stable at 
the cell surface than complexes containing other EGFR family members (Lenferink, Pinkas-
Kramarski et al. 1998).  Also, HER2 binding to EGFR decreases the rate of ligand dissociation 
from EGFR, even though HER2 itself does not bind to EGF (Karunagaran, Tzahar et al. 1996).  
As a result, there is prolonged EGF binding to EGFR in an EGFR-HER2 heterodimeric complex 
and thus longer activation of the EGFR signaling network (Figure 4.3).  Furthermore, 
heterodimers with HER2 remain on the cell surface longer and thus undergo endocytosis at a 
lower rate than EGFR homodimers do.  Moreover, an important reason for preference for the 
dimerization of EGFR-HER2 is that once the activated heterodimers are internalized, they are 
targeted for recycling instead of being targeted for degradation, as is the fate for EGFR 
homodimerization (Lenferink, Pinkas-Kramarski et al. 1998).  As a result of EGFR-HER2 
internalization, the recycling pathway returns the receptors to the cell surface to be ready for a 





There are thirteen recognized ligands that can bind to EGFR and its close family members.  
These ligands that bind to HER family receptors in a 1:1 stoichiometry are EGF itself, heparin-
binding (HB)-EGF, transforming growth factor (TGF) , amphiregulin (AREG), epiregulin 
(EREG), epigen (EPG), betacellulin (BTC) and neuregulins (NRG) 1 through 6 (which are also 
known as heregulins) that themselves can have different splice variants (Carpenter, Lembach et 
al. 1975, Marquardt, Hunkapiller et al. 1984, Weber, Bertics et al. 1984, Bajaj, Waterfield et al. 
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1987, Lax, Bellot et al. 1989, Shoyab, Plowman et al. 1989, Higashiyama, Abraham et al. 1991, 
Watanabe, Shintani et al. 1994, Komurasaki, Toyoda et al. 1997).  EGF-family ligands first have 
to be cleaved by metalloproteases, such as ADAMs, as they exist as membrane –anchored 
precursors.  When the products of cleaved, some of them have been implicated in transactivation 
of adjacent HER receptors, particularly HB-EGF while the carboxy-terminal remainder of the 
shed ligand might be functioning to activate intracellular signaling (Higashiyama, Iwabuki et al. 
2008).   
 
Even though there are many different ligands, some of them still have preferential binding to 
different Her family members (Eccles 2011) (Figure 4.3).  For EGFR, EGF and TGF  are two of 
the main ligands (Jorissen, Walker et al. 2003).  The L2 domain of EGFR seems to be the 
primary ligand-binding domain – more specifically, the L2 domain of EGFR and the small 
regions of the CR1 and CR2 flanking L2 bind EGF and TGF  with submicromolar affinity 
(Kohda, Odaka et al. 1993, Lemmon, Bu et al. 1997).  BTC can bind and regulate all of the 
receptors while NRG have preferences for ErbB3 and ErbB4 receptors.  There is evidence that 
depending on the ligand that binds to EGFR, different but specific patterns of EGFR 
phosphorylation can be formed that can determine the duration of signaling as well as the types 
of cellular responses (Eccles 2011).   For example, EGF stimulates motility and invasion less 
TGF  and AREGs possibly because EGF promotes more rapid ubiquitination and degradation of 




Figure 4.3.  This schematic illustration depicts the HER signaling network.   
At the membrane surface, HER receptor family members can bind to a number of different ligands (13 in 
total), with the exception of Her2 that does not bind to any ligand, following either homo-dimerization or 
hetero- dimerization.  As a result of receptor auto-phosphorylation as a result of dimerization, a number of 
adaptor proteins, enzymes, and second messengers are activated.  As a result, various cellular responses 
can be elicited upon HER receptor activation, including adhesion, growth, migration, differentiation and 






Downstream Signaling Pathways of EGFR 
 
 
In isolation, EGFR or any of its family members are inactive until a ligand binds to a receptor on 
the cell surface (Figure 4.4).  As a result, either homo- or hetero-dimerization of receptors occurs 
that allows for the cross-phosphorylation of tyrosine residues on the tyrosine kinase domains of 
the EGFR family members.  Consequently, phosphorylated docking sites attract adapter proteins 
and cytoplasmic enzymes that contain Src-homology 2 domains (SH2) such as Grb2, SHC, and 
PLC .  After dissociation of these complexes, activated effector and adapter proteins are released 
and follow to activate many downstream signaling pathways.  Following this activation is signal 
termination that is important to maintain a balance of pathway activation in the cell.  EGFR 
signal is inactivated primarily through endocytosis of the receptor-ligand complex. 
 
Figure 4.4.  A model for signal transduction mediated by epidermal growth factor receptor.   
When a ligand binds to EGFR on the cell surface, it induces dimerization and cross-phosphorylation with 
another receptor.  As a result, a signaling complex composed of effector and adaptor proteins is formed 
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and as it dissociates, it elicits downstream pathway activation. To terminate the signaling cascade, EGFR 
with ligands are internalized by endocytosis to clatherin-coated vesicles and the vesicles can either be 
degraded in the lysosomes or sent back to the cell surface for recycling of the receptors.  Adapted from 




EGFR: Kinase-dependent functions 
 
 
Upon ligand binding (EGF, HP-EGF, and TGF , among the preferred ones), EGFR becomes 
activated and as a result, it can recruit and phosphorylate a number of downstream signaling 
molecules (Figure 4.3).  Some of the pathways that EGFR can activate are the PI3K pathway, the 
Ras/MAPK pathway, the JAK2/STAT3 pathway as well as the PLC-  pathway (Anderson, Koch 
et al. 1990, Park, Schaefer et al. 1996, Bowman, Garcia et al. 2000, Navolanic, Steelman et al. 
2003, Lo 2010).  For example, when activated EGFR phosphorylates the signal transducer and 
activator of transcription 3 (STAT3) at residue Y705, it then subsequently triggers the 
dimerization, nuclear transport and gene regulation of STAT3 (Park, Schaefer et al. 1996, 
Bowman, Broome et al. 2001, Barre, Avril et al. 2003, Lo, Hsu et al. 2007, Lo, Cao et al. 2008).  
Activated STAT3 can result in epithelial-to-mesenchymal transition (EMT) by activating the 
expression of TWIST, an E-cadherin transcriptional repressor (Lo, Hsu et al. 2007).  
 
EGFR: Kinase-independent functions 
 
EGFR can mediate cellular processes independent of its ability to bind ligands or of its kinase 
activity, specifically by partnering with other proteins.  For example, EGFR has been shown to 
associate with p53-upregulator modulator of apoptosis (PUMA) independently of EGF 
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stimulation or its kinase activity (Zhu, Cao et al. 2010).  PUMA is a pro-apoptotic member of the 
Bcl-2 family of proteins that are primarily located in the mitochondria. As a result of this 
protein-protein interaction, PUMA will be sequestered to the cytoplasm and thus unable to 
trigger apoptosis.  Furthermore, more recently, EGFR localized within lipid draft microdomains 
in the membrane has been shown to activate Akt without the kinase activity of EGFR (Irwin, 
Bohin et al. 2011, Irwin, Mueller et al. 2011).  
 
EGFR: Nuclear functions 
 
EGFR has been detected in the nucleus of a variety of cancers, including that of breast, in recent 
studies (Lo, Hsu et al. 2005, Lo, Xia et al. 2005).  The current evidence indicates that nuclear 
EGFR is the full-length receptor that comes from the cell surface and is localized within the 
nucleoplasm and on the inner nuclear membrane (Cao, Lei et al. 1995, Lin, Makino et al. 2001, 
Lo, Hsu et al. 2005).  Some of the classes of nuclear functions for EGFR are: (1) its ability to act 
as a transcriptional regulator; (2) its ability to use its kinase domain in the nucleus; and (3) its 
ability to modulate DNA repair in the nucleus (Han and Lo 2012). 
 
 
Degradation and Recycling 
 
 
During signal termination, activated complexes with EGFR are then endocytosed via clatherin-
coated pits and two distinct processes can follow that determine the consequence of the 





EGFR degradation mechanism (1): Exposure and Binding to Clb  
 
The first of the two processes that are determining of the fate of EGFR complexes in the 
termination of signaling involves the ubiquitin ligase protein known as Cbl.  Once EGFR 
complexes are endocytosed, Clb can be recruited and in turn it interacts with a specific 
phosphorylated tyrosine residue on EGFR, Y1045, to shunt early endosomes through the 
degradative process (Levkowitz, Waterman et al. 1998).  When Cbl binds to EGFR, it 
ubiquitinates the receptor and thus targets it for lysosomal degradation.  In accordance with this 
model, when Y1045 is mutated, EGFR mitogenic signaling is strengthened, as compared to 




Figure 4.5. Interaction with Cbl determines the fate of internalized EGFR.   
Binding of Clb to internalized EGFR directs whether receptor complex is sent to the lysosome within 
thirty minutes of being endocytosed or sent back to the cell surface to be recycled and reused again.  In 
the absence of recruitment of Clb to the EGFR complex or in the presence of oncogenic Cbl (v-Cbl), 
  
76 
EGFR signaling can potentially continue by sending the EGFR complex back to cell surface to be re-
activated. Adapted from Levkowitz et al 1998. 
 
EGFR degradation mechanism (2): EGFR-complex stability  
 
The second important determining factor for the fate of EGFR complexes after endocytosis is the 
stability of the ligand-receptor complex itself (Figure 4.6) (Klapper, Kirschbaum et al. 2000).  
Inside the endosome, the environment is mildly acidic (pH of approximately 5.5).  In such 
conditions, only stable EGFR complexes are not dissociated, as in the case of EGFR homodimers 
that can remain bound to Cbl.  Since Cbl does not dissociate, Clb is able to ubiquitinate EGFR to 
target it to lysosomes to be degraded.   In the endosome, however, if EGFR is heterodimerized to 
HER2, the complex is more easily uncoupled in the early endosome, leading to the dissociation 
of Cbl from the receptor complex.  As a result of this less stable interaction between HER2 and 
EGFR, these receptors go through the route of default recycling and return back to the cell 
membrane to be reactivated (Figure 4.6). 
 
Figure 4.6. The impact of stability on internalized EGFR through interaction with Clb.   
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Given the pH of the endosome, heterodimers of EGFR with HER2 are less stable than EGFR 
homodimers. As a consequence, the EGFR-HER2 complex are dissociated, which releases Clb, and the 
heterodimer units are recycled back to the membrane.  On the other hand, stable EGFR –EGFR dimers 




EGFR/HER FAMILY Mice Models 
 
 
Various groups have generated mice that (1) lack the different members of the EGFR family of 
receptors, (2) mimic mutations that are thought to be oncogenic, (3) lack the ligands for EGFR 
family members, and (4) overexpress important ligands for their signaling activation (See Table 
4.1).  Particularly, mice that are knocked-out for EGFR highlight the importance of EGFR to 
embryonic and post-natal development (Miettinen, Berger et al. 1995, Sibilia and Wagner 1995, 
Threadgill, Dlugosz et al. 1995).   
 
Various groups observed that knock-out mice for HER2, HER3, and HER4 as well as mice 
lacking neuregulin (ligand that targets HER3 and HER4) display embryonic lethality with heart 
defects and abnormal nervous system development (Gassmann, Casagranda et al. 1995, Lee, 
Simon et al. 1995, Meyer and Birchmeier 1995, Riethmacher, Sonnenberg-Riethmacher et al. 
1997).  HER2, HER3, and HER4 seem to work in a cell-autonomous way during the 
development of Schwann cells, which are cells of glial origin that wrap axons in the peripheral 
nervous system and in post mitotic neurons, and the degeneration of neurons can be linked to the 
lack of factors secreted from Schwann cells (Riethmacher, Sonnenberg-Riethmacher et al. 1997, 
Britsch, Li et al. 1998, Lin, Sanchez et al. 2000).   
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Table 4.1.  List of mice that have been engineered to either have knock-out or knock-in of the 
multiple receptor members of the EGFR family as well as their ligands.   
Adapted from Sibilia et al 2007. 
 
Moreover, the effects of altering expression of the ligands for the EGFR family of receptors vary 
greatly than the multi-organ defects seen in the EGFR mutant mice models.  For instance, there 
is mild to no phenotype in the mammary gland, skin, and hair of mice expressing either over-
expression or deleted EGFR ligands such as EGF, amphiregulin (AR), and TGF  (Cook, 
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Piepkorn et al. 1997, Luetteke, Qiu et al. 1999, Chan and Wong 2000, Wong, Kwan et al. 2000).  
This suggests the possibly redundancy of ligands in the different organs to allow for these 
results. 
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Breast cancer can be classified into different molecular subtypes with varying clinical and 
pathological characteristics. The basal-like breast cancer subtype represents one of the most 
aggressive and lethal types of breast cancer, and due to poor mechanistic understanding, it lacks 
targeted therapy. Many basal-like breast cancer patient samples display alterations of established 
drivers of cancer development, including elevated expression of EGFR, p53 inactivating 
mutations, and loss of expression of the tumor suppressor PTEN; however, their contribution to 
human basal-like breast cancer pathogenesis remains ill-defined. Using non-transformed human 
mammary epithelial cells, we set out to determine whether altering EGFR, p53 and PTEN in 
different combinations could transform cells to mimic BBC. We modeled the molecular changes 





 cells, and analyzed them for in vitro cellular 
transformation.  Altering PTEN in combination with either p53 or EGFR in contrast to any of the 
single alterations caused increased growth of transformed colonies in soft agar. Concomitantly 
modifying all three genes further cooperated to show the highest rate of cellular proliferation and 
the greatest degree of anchorage-independent colony formation.  Results from our effort to 
engineer a model of BBC expressing alterations of EGFR, p53 and PTEN suggest that these 
changes are cooperative and likely have a causal role in basal-like breast cancer 
pathogenesis.  Consideration should be given to targeting EGFR and restoring p53 and PTEN 






Basal-like breast cancer, EGFR, PTEN, p53, dominant-negative, MCF10A, oncogene, tumor 




BC – breast cancer 
BCC – basal-like breast cancer 
PTEN – phosphatase and tensin homolog deleted on chromosome 10 
EGFR – epidermal growth factor receptor 
HER2 – human epidermal growth factor receptor 2 
p53DD – dominant negative p53 





Breast cancer (BC) is a heterogeneous disease characterized by at least five molecular subtypes: 
luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, normal-like, 
and basal-like (Sorlie, Perou et al. 2001).  Basal-like breast cancer (BBC), one of the most 
aggressive and lethal subtypes, comprises of 15-20% of all BC cases (Sorlie, Perou et al. 2001, 
Silva 2007). BBC itself is very heterogeneous, and according to the multi-platform analysis 
performed by the Cancer Genome Atlas Network, BBC expresses the highest frequency of 
mutations along with HER2-positive BC (Cancer Genome Atlas 2012, Shah, Roth et al. 2012).  
Furthermore, because BBC also generally lacks expression of estrogen receptor (ER), 
progesterone receptor (PR) and HER2, no targeted therapy is available for effective treatment 
(Sorlie, Perou et al. 2001, Dent, Trudeau et al. 2007).  Thus there is a necessity to create models 
of BBC in cell line systems that faithfully represent the alterations that are highly concurrent to 
allow us to better delineate the important molecular mechanisms that lead to this subtype of BC.  
 
This study focuses on alterations in three onco-proteins that occur at high frequency in BBC, 
namely epidermal growth factor receptor (EGFR), p53, and the phosphatase and tensin 
homologue deleted on chromosome 10 (PTEN) (Sorlie, Perou et al. 2001, Sorlie, Tibshirani et al. 
2003, Saal, Gruvberger-Saal et al. 2008, Cancer Genome Atlas 2012).  EGFR, a tyrosine kinase 
trans-membrane receptor stimulated by growth factors that can activate the mitogen-activated 
protein kinase (MAPK) and the phosphatidylinositol 3-kinase (PI3K) pathways, is altered in 
multiple cancers, and can be over-expressed in up to 70% of BBC cases (Livasy, Karaca et al. 
2006, Siziopikou and Cobteigh 2007).  PTEN, a negative regulator of the PI3K pathway, affects 
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proliferation, apoptosis, migration, genomic instability and metabolism (Maehama and Dixon 
1998, Stambolic, Suzuki et al. 1998, Sun, Lesche et al. 1999, Puc, Keniry et al. 2005, Puc and 
Parsons 2005, Smith 2012).  Decreased PTEN expression, through loss of heterozygosity, 
chromosomal rearrangement and/or epigenetic silencing, is observed in over 50% of all BBC 
cases and in 80% of familial BBCs (Perren, Weng et al. 1999, Depowski, Rosenthal et al. 2001, 
Saal, Holm et al. 2005, Carey, Perou et al. 2006, Saal, Gruvberger-Saal et al. 2008, Hu, Stern et 
al. 2009, Higgins, Beaver et al. 2011).  A recent paper suggests that inferred PI3K/AKT pathway 
alteration, which can be controlled by either EGFR and/or PTEN, is the highest in BBC among 
all BC subtypes (Cancer Genome Atlas 2012).  Additionally, the tumor suppressor p53, which is 
a regulator of apoptosis, DNA damage response, cell cycle and metabolism, has inactivating 
mutations in over 80% of BBCs (Sorlie, Perou et al. 2001, Carey, Perou et al. 2006, Turner and 
Reis 2006, Vousden and Ryan 2009, Cancer Genome Atlas 2012).  Furthermore, recent data now 
suggests that the TP53 pathway activity is altered within most, if not all BBCs (Cancer Genome 
Atlas 2012).  Taken together, EGFR, p53 and PTEN are altered at high frequency in a large 
subset of BBC cases, indicating the potential for these genes to cooperate in BBC initiation 
and/or progression in those tumors.  
 
The MCF10A cell line is a powerful cell culture model system for studying the genetic insults 
that can lead to breast cancer.  MCF10A cells are human, immortal, non-tumorigenic, mostly 
diploid and they lack CDKN2A (Soule, Maloney et al. 1990, Yoon, Wersto et al. 2002, Cowell, 
LaDuca et al. 2005, Higgins, Beaver et al. 2011).  These cells depend on growth factors and 
hormones for growth and survival, form polarized acini-like spheroids in a suspension of 
extracellular matrix (matrigel), grow in monolayers and do not grow in suspension in soft agar 
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unless they are transformed by expression of one or more onco-proteins (Soule, Maloney et al. 
1990, Debnath, Muthuswamy et al. 2003).  For example, the disruption of proper acini formation 
in MCF10A cells in matrigel has been shown to occur following knock-down of BRCA1 or after 
the expression of mutant alleles of PIK3CA, HER2, PCDH8K (mutant form of activated 
protocadherin-8), serine/threonine kinase AKT/PKB, human growth hormone (hGH), or co-
expression of EGFR with c-SRC (Muthuswamy, Li et al. 2001, Debnath, Walker et al. 2003, 
Furuta, Jiang et al. 2005, Isakoff, Engelman et al. 2005, Zhu, Emerald et al. 2005, Dimri, 
Naramura et al. 2007, Yu, Koujak et al. 2008).  MCF10A cells have been shown to grow in an 
anchorage-independent manner in soft agar without extracellular matrix following over-
expression of mutant H-RAS, HER2/NeuT (rat c-neu with single activating point mutation), or 
FGFR1 (Ciardiello, Mcgeady et al. 1990, Martinez-Lacaci, Kannan et al. 2000, Xian, Pappas et 
al. 2009).  Furthermore, MCF10A cells cluster closely with the BBC subtype in gene expression 
profiling studies and express markers commonly associated with a basal epithelial phenotype 
such as high-molecular weight cytokeratins and p63 (Perou, Jeffrey et al. 1999, DiRenzo, 
Signoretti et al. 2002, Neve, Chin et al. 2006).  They lack estrogen and progesterone expression 
and over-express the MYC oncogene, which is characteristically up-regulated in BBC, making 
these cells potentially suitable for modeling BBC tumor progression (Shekhar, Chen et al. 1998, 
Neve, Chin et al. 2006, Worsham, Pals et al. 2006). 
 
To date, we lack studies examining the effects of EGFR, p53 and PTEN mutations in 
combination in mammary epithelial cells. However, studies examining each alteration alone have 
been investigated.  MCF10A cells expressing a knock-in mutant EGFR (delE746-A750) 
displayed increased levels of total and phosphorylated EGFR, but had no advantage in growth or 
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in their ability to form colonies in soft agar (Di Nicolantonio, Arena et al. 2008).  MCF10A cells 
knocked out for p53 by Weiss et al. were able to grow in the absence of EGF (Weiss, Vitolo et 
al. 2010).  Over-expression of a truncated dominant-negative p53 (p53DD) did not affect 
proliferation rate in MCF10A cells in media supplemented with growth factors (Sheen and 
Dickson 2002).  Also, either knock down of p53 or the expression of dominant negative mutant 
p53 (G245S) in MCF10A cells led to near-normal acini structures with incompletely cleared 
lumen due to decreased apoptosis (Zhang, Yan et al. 2011).  MCF10A cells lacking PTEN 
exhibited increased signaling, enhanced growth on plastic, resistance to anoikis, but no increase 
in growth in soft agar (Vitolo, Weiss et al. 2009).  Therefore, in the above studies in MCF10A 
cells, single manipulations of EGFR, p53 or PTEN could affect different cellular properties 
important for tumorigenesis but none led to transformation of mammary cells as measured by the 
ability to grow in an anchorage independent manner.  Here, we show that EGFR over-expression 
together with inactivation of p53 and PTEN, alterations that are frequently observed in BBC, 








MATERIALS AND METHODS 
 
 
Cell culture   
MCF10A-PTEN-/- (clones 1 and 3) and their parental line were a kind gift from Kurtis Bachman 
(Glaxo Smith Kline) and Ben Ho Park (Johns Hopkins University) (Vitolo, Weiss et al. 2009). 
Cells were cultured at 37
0
C and 5% CO2 in DMEM/F12 50:50 (Fisher Scientific) media 
supplemented with 5% horse serum, 20 ng/ml of EGF, 10 µg/ml insulin, 0.5 mg/ml 
hydrocortisone, 100 ng/ml cholera toxin, and 1% penicillin/streptomycin solution. For signaling, 
cells were starved in DMEM/F12 media without growth factors overnight and washed twice with 
cold phosphate buffer saline (PBS) before lysis, as described below. All experiments were 
performed with two different MCF10A-PTEN-/- clones, which showed similar results. 
 
Retroviral production 
Stable cell lines were generated by serial viral infection of MCF10A or MCF10A-PTEN-/- cells 
with retroviral supernatants expressing pCMV-p53DD-hygromycin or pBABE-EGFR-
puromycin.  The p53DD vector was a generously kind gift from Moshe Oren (Weizmann 
Institute of Science, Israel) (Shaulian, Zauberman et al. 1992). The EGFR vector was obtained 
from Addgene (plasmid 11011) (Greulich, Chen et al. 2005).  Empty vectors for pCMV and 
pBABE were used as negative controls.  Retroviral production in phoenix cells was performed as 
previously described (Zhao, Gjoerup et al. 2003). Cultured viral supernatants were collected after 
48 hrs.  Cells were infected with filtered viral supernatants in the presence of 12 µg/ml 
polybrene. Post-viral infection, successfully transduced polyclonal population of cells was 
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obtained when selected with the appropriate drugs (hygromycin at 100 µg/ml for p53DD and 
puromycin at 1µg/ml for EGFR). 
 
Immunoblotting  
Cells were lysed in 1.25 M Tris-HCl, pH 6.8, 10% beta-mercaptoethanol, 10% sodium dodecyl 
sulfate (SDS), 20% glycerol, 0.5% bromophenol blue solution, and 8 M urea.  Protein lysates 
were boiled for 5 min and 25 µg of total protein was separated on 10% SDS-PAGE gels and 
transferred to polyvinylidene fluoride membranes. Membranes were blocked and incubated with 
primary antibodies followed by secondary antibody incubation.  The primary antibodies were 
PTEN (6H2.1, Cascade); EGFR (1005, Santa Cruz); phospho-tyrosine (4G10, Fisher); p53 (Ab-
1, Calbiochem); phospho-EGFR Y-1173 (Cell Signaling), AKT, phospho-AKT-S473, phospho-
AKT-T308, ERK-p44/42, phospho-ERK-p44/42 (all Cell Signaling); and actin (AC-15, Sigma).  
Membranes were developed with an enhanced chemoluminescence detection kit (SuperSignal 
West Pico, Fisher) according to manufacturer’s instructions.  
 
Proliferation assay 
MCF10A cells were plated in 48 well plates at a density of 1x10
4
 cells per well. At the indicated 
time points, cells were washed with PBS and fixed and stained with 0.05% crystal violet (JT 
Baker) in formalin for 20 min. Cells were rinsed 3 times with PBS to remove excess stain and 
allowed to dry overnight. Stained cells were analyzed by extracting the cell-associated dye with 
1 ml 10% acetic acid per well and shaking plates for 3 hrs at room temperature. Optical density 




Anchorage-independent soft agar growth assay 
For soft agar colony formation assays, 2.5x10
4
 MCF10A cells were seeded per 60 mm plate with 
a bottom layer of 0.6% Bacto agar (BD Biosciences) and a top layer of 0.3% Bacto agar, both in 
complete media. Colonies were photographed after 3 weeks of incubation and analyzed.  The 
total number of colonies per cell line was counted per plate.  Colonies were counted in at least 




Mice were housed in the mouse facility of the Irving Cancer Research Center and were treated in 
accordance with Columbia University Institutional Animal Care and Use Committee (IACUC) 
protocol AAAB-8776.  Six- to nine-week-old female immunocompromised scid mice (CB17/Icr-
Prkdc
scid
/IcrCrl) were obtained from Harlan Laboratories (NJ).  Xenograft experiments were 
performed by subcutaneous injection of 1-5x10
6
 cells resuspended in 100 µl of a 1:1 mix of cell 
suspension and matrigel (Trevigen). Mice were monitored for tumor growth by palpitation once 
a week and observed for a minimum of three months. Positive control for tumor formation 
employed was NeuT/PDK1 MCF10A cells (Maurer, Su et al. 2009). Each experimental group 
consisted of 10 animals, except for the positive control, which comprised of 8 animals.  
 
Statistical Analysis 
Proliferation rate and soft agar assays were analyzed using the Chi squared test, with a p-value ≤ 







Single modifications of PTEN, EGFR and p53 affect signaling  
We used MCF10A cells to construct a model system of BBC that stably expresses EGFR, p53 
and PTEN alterations to study the combinatorial effects of these genetic alterations on oncogenic 
transformation (Figure 1A). To develop a triple modified model of BBC, we first compared the 
effects of altering EGFR, p53 or PTEN alone. To examine the effects of EGFR, we stably over-
expressed wildtype EGFR via retroviral transduction in MCF10A cells and we showed that total 
EGFR protein level was significantly increased (Figure 1B). To model the effect of p53 
mutation, we stably over-expressed dominant negative p53 (p53DD) in MCF10A cells via 
retroviral transduction.  The p53DD is a carboxy-terminal fragment of p53 that forms 
functionally impaired multimers with the wildtype endogenous p53 to abrogate sequence-
specific DNA binding (Shaulian, Zauberman et al. 1992).  Multiple groups have shown the 
effectiveness of p53DD in cancer models (Zhao, Liu et al. 2005, Utermark, Schaffhausen et al. 
2007). The ectopic expression of p53DD was verified using an antibody to the carboxy-terminal 
region in the truncated mutant (Figure 1C).  Next, to model PTEN inactivation, we utilized 
MCF10A cells that harbored a targeted deletion of exon 2 of PTEN (MCF10A-PTEN-/-) (Vitolo, 
Weiss et al. 2009).  We validated that MCF10A-PTEN-/- cells express no PTEN protein as 
compared to the parental line (Figure 1D).  Each of these three alterations models changes to 
EGFR, TPp53, and PTEN genes that are found in the majority of BBC tumors and can be 




To verify that the changes to EGFR, p53, or PTEN had the predicted functional effects, we 
investigated signaling in our models. Cells expressing EGFR, p53DD or PTEN loss were starved 
overnight and total protein lysates were analyzed by Western blot. We showed that the EGF 
receptor was functionally active by the increased total tyrosine phosphorylation on EGFR in the 
cells over-expressing EGFR as compared to control cells (Figure 1B).  To show p53DD was 
functional in our system, we detected decreased level of p21, a critical cell cycle downstream 
effector of p53 activation (Figure 1C).  AKT activation at serine-473 was increased by PTEN 
mutation (Figure 1D). Therefore, we observed signaling changes that were expected as the result 
of over-expressing EGFR, p53DD or losing PTEN in our system.  
 
EGF-independent growth is feasible only in PTEN-null cells and not in EGFR- or p53DD-
expressing MCF10As  
We characterized the growth properties of MCF10A cells harboring over-expression of EGFR, 
p53DD, or loss of PTEN to compare each alteration’s effect on proliferation under starved 
conditions.  Non-transformed cells are dependent on growth factor signaling for their ability to 
proliferate; thus, in the absence of the appropriate mitogenic signals, they do not grow 
(McCormick 1999).  Proliferation was determined by assessing the relative cell accumulation at 
different time points, as previously described (Serrano, Lin et al. 1997).  Cells were maintained 
in media devoid of any growth supplement for a period of 20 days. When cells expressing 
different single alterations were compared for their ability to grow, we observed distinct 
differences in their proliferation capacity.  Consistent with prior observations (Vitolo, Weiss et 
al. 2009), loss of PTEN allowed cells to proliferate without growth factor stimulation (Figure 
2A).  MCF10A cells expressing EGFR or p53DD did not proliferate under identical conditions. 
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Therefore, whereas losing PTEN expression alone was an instigator for cell growth in the 
absence of growth factors, exogenous expression of either EGFR or p53DD was not. 
 
Growth in soft agar is not permissible by altering EGFR, p53 or PTEN individually 
Anchorage-independent growth in soft agar is a property of transformed cells that best correlates 
with in vivo tumorigenesis (Shin, Freedman et al. 1975, Cifone and Fidler 1980).  Therefore, we 
sought to determine the anchorage-independent capacity of any single alteration in MCF10A 
BBC model cells to grow in soft agar. MCF10A cells are non-transformed cells and by 
themselves do not to form colonies in soft agar, as previously established (Jiang, Jimenez et al. 
1999).  MCF10A cells that over-expressed oncogenic H-RasV12, as our positive control cells, 
induced colonies in soft agar (Figure 2B), as previously reported (Ciardiello, Mcgeady et al. 
1990). However, none of the singly-modified MCF10A cells grew as colonies in soft agar.  This 
is in agreement with previous studies reporting that neither an EGFR activating mutant nor a 
PTEN-null mutant can induce colony formation when expressed in MCF10A cells (Dimri, 
Naramura et al. 2007, Vitolo, Weiss et al. 2009).  It has also been shown that p53DD expression 
in hTERT-immortalized human mammary epithelial cells does not grow in soft agar (Utermark, 
Schaffhausen et al. 2007).  Therefore, individually, none of these three alterations in MCF10A 
cells confer anchorage-independent growth property in soft agar. 
 
Loss of PTEN affects proliferation regardless of presence of EGFR or p53DD  
After analyzing the signaling and growth phenotype of cells expressing only one alteration at a 
time, we engineered cells to express two alterations to study their combinatorial effect for BBC 
modeling.  We stably over-expressed wildtype EGFR and/or p53DD in MCF10A or MCF10A-
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PTEN-/- cells to generate the three new experimental cell lines, herein named EGFR-p53DD, 
p53DD-PTEN-/- and EGFR-PTEN-/-.  Additionally, we stably expressed the control vectors as 
our control line, herein ctrl.  PTEN-/- cells expressing EGFR or p53DD grew better than EGFR-
p53DD or ctrl cells, neither of which grew under starvation conditions (Figure 3A). Interestingly, 
neither EGFR-PTEN-/- or p53DD-PTEN-/- cells grew significantly better than PTEN-/- cells 
alone, suggesting that exogenous expression of EGFR or p53DD did not confer a growth 
advantage under the same conditions.  Overall, the increased proliferation due to PTEN loss was 
not affected by co-expression of either EGFR or p53DD. 
 
Either EGFR or p53DD cooperates with PTEN loss for anchorage-independent colony 
growth in soft agar 
Given that MCF10A cells with alterations in EGFR, p53 or PTEN were not able to confer 
anchorage-independent growth individually, we sought to find out if double combinations of 
those altered genes would allow for soft agar colony formation. We observed that the double-
modified EGFR-PTEN-/- and p53DD-PTEN-/- cells were capable of growing colonies in soft 
agar suspension (Figures 3B and C). On the other hand, EGFR-p53DD did not cooperate to 
transform cells as measured by growth in soft agar.  We showed the double-modified cells 
expressing PTEN-/- as one of their alterations grew statistically significantly more colonies when 
compared to EGFR-p53DD (P=9.2x10
-9
 when comparing EGFR-p53DD to p53DD-PTEN-/-). 
The lack of soft agar growth by EGFR-p53DD cells is consistent with their significantly lower 
AKT activation at threonine-308 residue compared to EGFR-PTEN-/- and p53DD-PTEN-/- cells 
that formed colonies (Figure 3D, lane 1 compared to lanes 2 and 3).  These experiments 
demonstrate that although EGFR-p53DD did not cooperate to grow in suspension in soft agar, 
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PTEN loss with either EGFR or p53DD did significantly synergize to grow colonies in an 
anchorage-independent fashion. Interestingly, EGFR-PTEN-/- cells grew on average twice as 
many colonies per plate as compared to p53DD-PTEN-/- cells (P=1.6x10
-5
; Figure 3C), 
consistent with the known effects of EGFR signaling on additional tumor-promoting signaling 
pathways. This result is consistent with higher phosphorylation and activation of AKT at 
threonine-308 in EGFR-PTEN-/- cells as compared to p53DD-PTEN-/- cells (Figure 3D, 
compare lanes 2 and 3). Therefore, the ability of either p53DD or EGFR to potentiate soft agar 
growth in the context of PTEN mutation suggests that either altered p53 or EGFR have the 
potential to cooperate with PTEN loss to stimulate tumor progression.  
 
Increased synergy for growth by co-expression of PTEN, EGFR and p53 in cells 
Next, we investigated whether all three alterations together could show cooperation beyond what 
was observed with the double changes.  Cells stably expressing all three changes, herein called 
EGFR-p53DD-PTEN-/-, were compared to the other modified cells for their ability to grow in 
media devoid of all growth factors.  Strikingly, we observed enhancement in the rate of growth 
of EGFR-p53DD-PTEN-/- cells as compared to the various double-modified cell lines.  Our 
triple-modified cells proliferated significantly more than any of the PTEN-null double-modified 
cells (P=0.04) or the ctrl cell line (P=0.007) (Figure 3A).  Therefore, we observed the greatest 
cooperation in proliferative ability when all three alterations were concomitantly present.   
 
We also compared the ability of the triple-modified cells to grow colonies in soft agar relative to 
the double-modified lines (Figure 3B-C).  Our results with soft agar show that when all three 
alterations were expressed together, the transformation phenotype became more pronounced 
  
95 
(Figure 3B). There was a statistically significant increase in the average number of colonies in 
EGFR-p53DD-PTEN-/- cells as compared to the double-modified cells capable of growing in 





Figure 3C).  Therefore, we showed that concomitant alteration of EGFR, p53, and PTEN 
maximized the number of colonies in soft agar, a characteristic of transformed cells.  The triple 
modified cells were unable to form tumors in SCID mice (n=10) after at least 3 months (Table 
1).   
 
Triple-modified cells had a notable difference in signaling as compared to the double-modified 
lines.  Whereas AKT activation in EGFR-PTEN-/- cells showed a similar degree as the EGFR-
p53DD-PTEN-/- cells, EGFR activation was highest in EGFR-p53DD and the triple-modified 
cells (Figure 3D).  Therefore high activation of both the AKT and EGFR signaling was seen only 
in the triple modified cells.  We observed no ERK activation difference between the double- and 
the triple-modified cells. We conclude that the triple modified line was unique in its activation of 













The ultimate goal of human cancer models is to manipulate genes that are altered in human 
tumors to demonstrate whether their expression can lead to tumorigenesis of normal cells.(Dimri, 
Band et al. 2005, Saal, Holm et al. 2005) Previous human mammary epithelial cancer cell 
models have provided important insights into critical pathways involved in cancer formation 
(Elenbaas, Spirio et al. 2001, Isakoff, Engelman et al. 2005, Gustin, Karakas et al. 2009, Maurer, 
Su et al. 2009, Vitolo, Weiss et al. 2009, Kadota, Yang et al. 2010, Weiss, Vitolo et al. 2010). 
EGFR, p53, and PTEN alterations frequently occur in a relatively large proportion of the basal-
like subtype of breast cancer, but their combinatorial expression has not been examined for 
cancer initiation in mammary epithelial cells.  Therefore, we sought to determine if these three 
onco-proteins are able to faithfully model initiation of BBC when expressed in MCF10A cells 
has been a well-established model for studying the effects of genes in mammary tumorigenesis 
(Muthuswamy, Li et al. 2001, Debnath, Muthuswamy et al. 2003, Debnath, Walker et al. 2003, 
Isakoff, Engelman et al. 2005, Xian, Pappas et al. 2009).  Here, we demonstrate that EGFR, p53 
and PTEN together play a role to bestow some features of cellular transformation on MCF10A 
cells.  Our findings suggest that coincident molecular alterations of these three genes contribute 
to BBC pathogenesis. 
 
We demonstrate that cooperation between EGFR, p53DD and PTEN loss caused transformation 
of MCF10A cells as measured by having both the ability to grow in the absence of growth 
factors and in suspension in soft agar.  As cells become transformed, they lose their dependence 
on growth factors and are able to grow devoid of them (Hahn, Counter et al. 1999).  As a single 
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event, losing PTEN was the most important alteration in mammary epithelial cells as it was the 
only alteration to cause them to grow in the absence of mitogenic stimuli.  When all three 
alterations were expressed, our results indicated an additive effect as cells grew the fastest in this 
triple combination in the absence of growth factors.  However, no single alteration was able to 
induce growth in soft agar. As for anchorage independence, the ability of cells to grow in 
suspension was only permitted when PTEN loss cooperated with either loss of p53 function 
through p53DD expression or EGFR over-expression. Thus loss of PTEN synergized with p53 or 
EGFR alteration in this setting.  Further synergy in soft agar was observed when all three 
alterations were expressed together to form two- to four-fold more colonies as compared to the 
double-modified cells.  The additive effect observed when EGFR, p53 and PTEN are all altered 
in the anchorage-independent assay is in accordance with the model for cancer progression 
where a series of stepwise alterations have to accrue for cells to become transformed and display 
the different hallmarks of cancer (Farber 1984, Hanahan and Weinberg 2000). 
 
As the differences in AKT and EGFR activation were only modest between EGFR-PTEN-/- and 
EGFR-p53DD-PTEN-/- (triple-modified) cells, the AKT and EGFR pathways alone may not 
explain the differences in phenotype between the aforementioned double- and triple-modified 
cells, although both of these pathways appear to be critical.  However, the substantial difference 
in phenotype between EGFR-PTEN-/- and triple-modified cells would indicate an important 
selective pressure to inactivate p53, which is highly supported by data showing that 4/5 of BBCs 
have mutations in p53 or in a component of its pathway (Cancer Genome Atlas 2012).  Further 
work is needed to identify the important target proteins coordinating the advantage gained by the 
triple-modified cells. We know that altering EGFR, p53 and PTEN pathways can regulate a 
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myriad of crucial functions such as proliferation, apoptosis, protein translation, metabolism, 
DNA damage response, and cell cycle, which is likely why the triple-modified cells grow better 
than the double-modified cells.   
 
Altered EGFR, p53 and/or PTEN have been previously shown to cooperate in various other 
systems to induce transformation. For instance, PTEN mutation has been shown to cooperate 
with EGFR activation in human glioblastoma (Pore, Liu et al. 2003).  Inactivation of both PTEN 
and p53 was sufficient to induce invasive prostate cancer in a mouse model but inactivation of 
just one alteration was not sufficient for tumorigenesis (Chen, Trotman et al. 2005).  The 
cooperation between EGFR and p53 was shown to expand a subpopulation of esophageal cells to 
go through epithelial-to-mesenchymal transition, a phenotype of transformed cells (Ohashi, 
Natsuizaka et al. 2010).   Similar to the above studies in other systems, we have also shown 
evidence that PTEN deletion cooperates with p53 and/or EGFR alteration in mammary epithelial 
cells. 
 
Our novel BBC cell line models exhibit EGFR up-regulation via over-expression of the wildtype 
protein, though it is additionally plausible that tumorigenesis of the mammary gland may be 
attributed to variant forms of EGFR or epigenetic changes in EGFR. In other cancers that 
typically display EGFR up-regulated at the protein level, such as lung cancer, glioblastoma, and 
ovarian cancer, the existence of EGFR variants has been established to contribute to 
tumorigenesis (Lassus, Sihto et al. 2006, Sharma, Bell et al. 2007, Hatanpaa, Burma et al. 2010, 
Wang, Zhou et al. 2011).  One of the most potent EGFR variants, EGFR-VIII, that is a well-
known constitutively active variant occurring in glioblastoma, has been shown to dimerize with 
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wildtype EGFR (Hatanpaa, Burma et al. 2010).  In colon cancer, mutation in the 3’ –untranslated 
region (UTR) of EGFR has been shown to be a mechanism that contributes to the up-regulation 
of this receptor (Yuan, Shin et al. 2010).  Therefore, mutant forms of EGFR found rarely in 
breast cancer could also contribute to BBC tumor progression (Piccione EC 2011, Teng, Tan et 
al. 2011, Del Vecchio CA 2012). 
 
Here we showed that EGFR, p53 and PTEN alterations cooperate in MCF10A cells to drive 
transformation as measured by the increase in oncogenic signaling, growth factor independent 
growth and the ability to be anchorage-independent. Our cell line models expressing PTEN loss 
with EGFR and/or p53DD that can drive in vitro BBC progression may be used in future studies 
to identify additional driver genes capable of enhancing oncogenic progression.  Importantly, our 
triple modified MCF10A cell line system for BBC provides a novel platform for 
pharmacological studies to explore triple targeted therapy of these three genes to prevent tumor 

















Table 1.  Xenografts of engineered MCF10A cells in 
immunocompromised scid mice to test in vivo 
tumorigenicity 
 
ENGINEERED CELL LINE  
 
TUMOR GROWTH 
+ EGFR 0/10 
+ p53DD 0/10 
+ PTEN-/- 0/10 
+ EGFR-p53DD 0/10 
+ p53DD-PTEN-/- 0/10 
+ EGFR-PTEN-/- 0/10 
+ EGFR-p53DD-PTEN-/- 0/10 
+ vector (- control) 0/10 










































Figure 1. Modeling basal-like breast cancer by altering EGFR, p53 and PTEN in MCF10A.   
(A) Analysis of loss of PTEN, overexpression of EGFR or loss of p53 function has not shown to be 
oncogenic on their own in mammary epithelial cells. Given the high incidence of these alterations in 
basal-like breast cancer (BBC), we hypothesize that loss of PTEN, over-expression of EGFR, loss of p53 
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function through dominant negative p53 (p53DD) together can cooperate to transform MCF10A cells for 
a model of BBC. (B) EGFR stable over-expression alone and an empty control cassette were expressed in 
MCF10A cells.  Total and phospho-tyrosine EGFR antibodies were probed to show EGFR was 
functionally active.  (C) Expression of amino-terminal deletion mutant p53 (p53DD) to abrogate p53 
function or empty control in MCF10A cells.  Lysates were probed with antibody targeting the remaining 
p53 carboxy-terminal domain. Functional validation of p53DD by lower p21 level in the p53DD sample. 
(D) We utilized MCF10A-PTEN-/- cells deleted for exon 2 and we confirmed that PTEN protein was not 
present compared to the parental cells. For C-D, whole protein lysates were harvested after overnight 





Figure 2.  In vitro oncogenic properties of singly-modified MCF10A cells.   
(A) MCF10A cells expressing EGFR, p53DD, PTEN loss, or empty control were plated in 48 well plates 
in quadruplicates and grown without growth factors for a period of 20 days.  Cells were stained with 
crystal violet dye at days 0, 5, 13 and 20 and analyzed for growth rate differences. The means ± SD for 
the four experiments are shown and statistical analysis was calculated by chi-test. (B) Soft agar assay of 
MCF10A cells test for anchorage-independence ability of each single alteration in MCF10A cells.  
MCF10A cells over-expressing constitutively active mutant RAS (RASV12) was utilized as an internal 
positive control for this assay. The means ± SD for the three experiments are shown and statistical 






Figure 3.  Double- and triple- modified cells grow in absence of stimuli and in soft agar.   
(A) Proliferation growth difference was assessed for the double- and triple-modified cells.  Cells were 
plated in quadruplicates and grown in 48-well plates in media lacking growth factors for a period of 20 
days before staining cells with crystal violet dye for analysis.  As a double-modified control, empty 
control vectors for both pBABE-PURO and pCMV-HYG (herein named ctrl) were expressed in MCF10A 
cells.  The means ± SD for the four experiments are shown and P values were calculated by chi-test. (B-
C) Soft agar colony assay for the double- and triple-modified cells to show their ability to form colonies 
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in an anchorage-independent fashion. Each cell line was done in triplicates. Representative photographs 
of colonies were taken at 4X magnification.  The means ± SD for the three experiments for each line are 
shown and P values were calculated by chi-test. (D) Signaling was measured for the double- and triple-
modified lines. Cell lysates were harvested after overnight starvation and analyzed for EGFR, AKT and 
ERK signaling. Western blot exposures for each antibody were taken from the same blot and irrelevant 





Figure 4. A model for BBC transformation in MCF10A.   
We demonstrate that our triple-modified cell line model for BBC expressing three of its highly occurring 
somatic alterations (EGFR, p53, PTEN) was capable of transforming MCF10A cells as shown by growth 
in the absence of growth factors and anchorage-independent colony formation in soft agar. This current 
model can be a useful platform for triple targeted therapies to be tested for efficacy of treatment for BBC. 
Lastly, given the heterogeneity of BBC tumors, additional genetic and/or epigenetic changes are likely 
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Epidermal growth factor receptor (EGFR) is known to be up-regulated in the majority of breast 
cancers of one of the most lethal types, the basal-like subtype (BBC). However, the mechanism 
by which EGFR is over-expressed in BBC is very poorly understood as EGFR amplifications 
only account for approximately 1% of BBC.  In cancers of other origins where EGFR is also 
commonly up-regulated at the protein level, such as glial and lung cancers, the mechanism of up-
regulation of EGFR activity has been accounted by alterations of this tyrosine kinase receptor at 
the genetic level.  Reports of genetic alterations of EGFR have been very controversial over the 
years.  We chose to investigate whether different variants of EGFR exist in BBC.  We screened a 
panel of basal-like breast cancer cell lines for possible gross alterations of EGFR at the cDNA 
level by designing three sets of primers covering the whole region of EGFR. We analyzed and 
sequenced the RT-PCR amplicons that ran at a different size from cDNA of EGFR from normal 
pool of breast tissue.  We identified five different variant forms of EGFR, each originating from 
a different BBC cell line.  There were three types of mutations – in-frame deletions of the 
extracellular domain; in-frame deletion of the carboxyl end; and an exon duplication. Variants 
showed stronger sustained activation of the receptor itself under starved conditions as well as 
evidence for lack of EGFR degradation upon ligand stimulation.  Most variants gave a growth 
advantage over wildtype EGFR in semi-starved conditions. One novel EGFR variant (BL29), 
deleted in the regions very similar to those deleted in a known truncated oncogenic EGFR 
(EGFRVIII), was more migratory, invasive, and conferred normal mammary cells the ability to 
be anchorage-independent. We have identified a common genetic mechanism for EGFR 
deregulation in BBC cells that could account, in part, for the up-regulation of EGFR in tumors of 
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the BBC subtype. Priority should be given to screen and examine recurrence of these alterations 
in tumors derived from BBC to validate their biological importance and contribution to the 
process of tumorigenesis in breast cancer.  The relevance of this discovery of novel EGFR 
variants in breast cancer is the ability to hopefully identify new targetable forms of receptors to 







Epidermal growth factor receptor (EGFR) is often deregulated in multiple different types of solid 
tumors, including breast, ovarian, lung, and brain cancers.  Breast cancer occurs in about one in 
every eight women and can be classified based on gene expression profiling into about five 
different subtypes, with the basal-like subtype accounting for approximately 15-20% of all cases. 
Basal-like subtype of breast cancer is characterized by the lack of hormone receptors Her2, 
estrogen and androgen; and because of its aggressive nature and current lack of targeted therapy, 
this subtype is highly lethal. Tumors from patients with this cancer typically show upregulation 
of EGFR by immunohistochemistry.  
 
EGFR is part of the ErbB family of cell surface receptor tyrosine kinase proteins that are 
involved in a myriad of critical cellular functions such as proliferation, apoptosis, migration, and 
angiogenesis. In response to ligands, such as EGF, transforming growth factor alpha or 
epiregulin, these transmembrane receptors dimerize with other EGFR species to form monomers 
or with other members of the ErbB family, such as Her2, to form heterodimers.  Dimer formation 
brings together in close physical space the intracellular kinase domains of each dimer partner and 
leads to autophosphorylation of key tyrosine residues that activate downstream signaling 
pathways mediated by PI3K-Akt-mTOR, Ras-Raf-Mek, PLC -PKC, and JAK2-STAT3.  
 
Taking into observation that EGFR, when its protein is up-regulated in human cancers, it is often 
found to be altered at the DNA or RNA level, we stipulated that basal-like breast cancers that 
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show upregulation of EGFR would likely be caused by a similar mechanism.  Thus our 
hypothesis was that  altered forms of EGFR in basal-like cancers can be found that are either 
working with wildtype EGFR, such as the case of EGFR-VIII, or partnering with another 
protein, possibly another member of the ErbB family of receptors.  
 
We decided to do a screen of various basal-like breast cancer cell lines by analyzing the mRNA 
transcript. Previous papers have shown that they could not find mutant forms of EGFR but most 
screens were made at the DNA level and by sequencing the boundaries of the exons. The 
strategy utilized here was to amplify large regions of EGFR mRNA -- the complete 28-exon 
spanning mRNA was divided into three regions and primers were made to flank each major 
region, with overlapping ends for full coverage. We found a surprisingly large number of species 
of EGFR that were not the size of wildtype EGFR that co-expressed with the normal form of the 
protein and their sequence revealed EGFR variants that lacked regions of the N-terminal, C-
terminal and tyrosine kinase domain.  We demonstrated that various of these novel EGFR 
variants can positively alter growth capability, allow for more sustained signaling upon 
starvation, and cause a more invasive phenotype with a corresponding ability to allow cells to 






MATERIALS AND METHODS 
 
 
Cell culture   
MCF10A cells (obtained from ATCC) and Hmec-hTERT cells (a kind gift from Dr. Robert 
Weinberg at Massachusetts Institute of Technology) were cultured at 37
0
C and 5% CO2. 
MCF10A cells were cultured in DMEM/F12 50:50 (Fisher Scientific) media supplemented with 
5% horse serum, 20 ng/ml of EGF, 10 µg/ml insulin, 0.5 mg/ml hydrocortisone, 100 ng/ml 
cholera toxin, and 1% penicillin/streptomycin solution.  Hmec-hTERT cells were cultured in 
DMEM/F12 50:50 (Fisher Scientific) media supplemented with 10 ng/ml of EGF, 10 µg/ml 
insulin, 0.5 ug/ml hydrocortisone (Sigma), and 1% penicillin/streptomycin solution.  For 
signaling, cells were completely starved in DMEM/F12 media without growth factors overnight 
and washed twice with cold phosphate buffer saline (PBS) before lysis, as described below.  
 
cDNA synthesis and RT-PCR 
cDNA was synthesized from RNA primed with random hexamers (Amersham Biosciences, 
Piscataway, NJ, USA). Primers used for reverse transcription (RT)–PCR:  5’ UTR region: 
forward primer 5’ –CCAGTATTGATCGGGAGAGC- 3’ and reverse primer 5’-
TGCAGCTGTTTTCACCTCTG -3’; middle EGFR region: forward primer 5’ –
GGGGTGACTCCTTCACACAT -3’ and  reverse primer 5’-CTGCGGTGTTTTCACCAGTA-
3’; 3’UTR region: forward primer  5’ –CTGGATCCCAGAAGGTGAGA- 3’ and  reverse 
primer 5’-CGCGACCCTTAGGTATTCTG – 3’.  An alternative 5’ UTR region sequence was 
used when no RT-PCR product was seen with the sequence aforementioned: forward primer 5’ –
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GGGCTCTGGAGGAAAAGAAA- 3’ and reverse primer 5’-TGTGGATCCAGAGGAGGAGT 
-3’. 
 
Site-directed Mutagenesis for EGFR Deletion Variants 
To create the EGFR variants to be studied, the Stratagene QuikChange II XL Site-Directed 
mutagenesis kit was used to create the four deletion variants in the pBABE-EGFR-PURO 
expression vector as per manufacturer instructions. The primers used for BL29 mutation:  
forward primer 5’- CC AGA GGA TGT TCA ATA A CTA TGA GAT GGA GGA AGA C -3’ 
and reverse primer 5’- G TCT TCC TCC ATC TCA TAG TTA TTG AAC ATC CTC TGG -3. 
The primers used for BL32 mutation: forward primer 5’- GAC TAT GTC CGG GAA CAC 
AAA GAC AAC CCT GAC TAC CAG CAG GAC -3’ and reverse primer 5’- GTC CTG CTG 
GTA GTC AGG GTT GTC TTT GTG TTC CCG GAC ATA GTC -3. The primers used for 
BL33 mutation: forward primer 5’- CTT TCC TTC TTA AAG GTC TGC CGC AAA TTC CG -
3’ and reverse primer 5’- CG GAA TTT GCG GCA GAC CTT TAA GAA GGA AAG -3. The 
primers used for BL54 mutation: forward primer 5’- CCT TTGCCT TTG GAA AAC CTG ACC 
TGC CCC CCA CTC ATG -3’ and reverse primer 5’- CAT GAG TGG GGG GCA GGT CAG 
GTT TTC CAA AGGCAA AGG -3’.  TOPO TA Cloning (Invitrogen) was used to get single 
clones of PCR fragments. To screen clones grown for those with the correct size of the desired 
variants, we digested the site-directed mutagenesis clones with NaeI restriction enzyme that cuts 
only once inside  EGFR sequence and once outside the EGFR within the pBABE-PURO vector.  
Clones were then sequenced to confirm the presence of the mutations and analyzed using the 




Cloning of Exon 20 Duplication in EGFR 
To create the full in-tandem exon 20 duplication of EGFR that was detected in the MDA-MB-
436 cell line, we used restriction enzyme digestion (DRAIII and BglII) of unique sites that were 
found flanking outside of exon 20 of the PCR fragment that the mutation was detected from RT-
PCR screen that encompassed from exon 17 of EGFR to exon 25.  The same enzymes were used 
to excise out the wildtype region in the pBABE-EGFR-PURO vector and the mutated, longer 
fragment was ligated into the set vector.  For analysis of correct ligation, PCR was run on the 
new pBABE-ex20dEGFR-PURO vector against pBABE-EGFR-PURO vector using the forward 
primer Universal T7 and the reverse Universal T3 that are found within the vector.  We 
confirmed the duplication was correctly inserted by showing an increase of 186 nucleotides in 
the exon 20 duplication mutant fragment in the vector. Samples were run on an electrophoresis 
gel to detect band size difference -- the bands were then cut out and sent to be sequenced for 
final validation. 
 
Validation of exon 20 duplication in genomic DNA of MDA-MB-436  
We designed primers such that only when there is a duplication of exon 20 then there will be an 
amplicon after PCR of the genomic DNA of the MDA-MB-436 cell line: forward primer 5’- 
GCTCCCAGTACCTGCTCAAC – 3’ and reverse primer 5’- CTGCGTGATGAGCTGCAC – 
3’.  The forward primer lies at the end of exon 20 of EGFR whereas the reverse primer lies at the 






Array Comparative Genomic Hybridization (aCGH) 
Experiments using the 64K BAC aCGH platform were performed by using described method. A 
custom-design complementation array (Agilent) was also used as described
. 
In brief, this HD-
aCGH microarray contains 1,797 probes in replicates covering a region of ~588 kb centered on 
the EGFR locus at a mean spacing of 327 bp, and an additional ~20,000 probes with wide 
genome coverage that are used for data normalization with the pop Lowess algorithm. Labeling 
and hybridization were performed according to the manufacturer’s recommendations, and data 





Stable cell lines were generated by serial viral infection of cells with retroviral supernatants 
expressing pBABE-EGFR-PURO or one of the EGFR variants that were cloned into the parental 
vector aforementioned. The EGFR vector was obtained from Addgene (plasmid 11011) 
(Greulich, Chen et al. 2005).  Empty vector for pBABE-PURO was used as negative control.  
Retroviral production in phoenix cells was performed as previously described (Zhao, Gjoerup et 
al. 2003). Cultured viral supernatants were collected after 48 hrs.  Cells were infected with 
filtered viral supernatants with 0.48µm filters in the presence of 12 µg/ml polybrene. Post-viral 
infection, successfully transduced polyclonal population of cells was obtained when cells were 
selected with puromycin at 1µg/ml. 
 
Immunoblotting  
Cells were lysed in 1.25 M Tris-HCl, pH 6.8, 10% beta-mercaptoethanol, 10% sodium dodecyl 
sulfate (SDS), 20% glycerol, 0.5% bromophenol blue solution, and 8 M urea.  Protein lysates 
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were boiled for 5 min and 25 µg of total protein was separated on 10% SDS-PAGE gels and 
transferred to polyvinylidene fluoride membranes. Membranes were blocked and incubated with 
primary antibodies followed by secondary antibody incubation.  The primary antibodies were 
EGFR (1005, Santa Cruz); phospho-EGFR Y-1173 (Cell Signaling), AKT, phospho-AKT-S473, 
phospho-AKT-T308, ERK-p44/42, phospho-ERK-p44/42 (all Cell Signaling); and actin (AC-15, 
Sigma).  Membranes were developed with an enhanced chemoluminescence detection kit 
(SuperSignal West Pico, Fisher) according to manufacturer’s instructions.  
 
Proliferation assay 
Hmec-hTERT cells were plated at a density of 4x10
4 
cells per well.  To culture in semi-starved 
media, cells were plated in DMEM:F12 media with only 5% of the total growth factor 
supplementations added back in (as already described).  To culture in semi-complete media, cells 
were plated in DMEM:F12 media with 50% of the total growth factor supplementation added 
back in.  To culture in media lacking EGF or insulin, cells were plated in their regular media 
with the exception of the addition of EGF or insulin. At the indicated time points, cells were 
washed with PBS and fixed and stained with 0.05% crystal violet (JT Baker) in formalin for 20 
min. Cells were rinsed 3 times with PBS to remove excess stain and allowed to dry overnight. 
Stained cells were analyzed by extracting the cell-associated dye with 1 ml 10% acetic acid per 
well and shaking plates for 3 hrs at room temperature. Optical density was measured at 565 nm. 






Transwell migration/invasion assay 
1×10
4
 Hmec-hTERT stable cells were plated in upper chamber of 8-micron 24-well Transwell 
cell culture plates (Costar) in DMEM:F12 media lacking any growth factors.  The membrane of 
the upper chamber was previously coated with matrigel to assay for invasion.  Complete media 
(DMEM:F12, 0.25μg/ml hydrocortisone, 10μg/ml insulin, 10 ng/ul EGF and 5% penicillin/ 
streptomycin) was placed in the lower chamber. Cells were allowed to migrate/invade for 12 
hours before cells were stained with crystal violet for 20 minutes and cells were counted that 
crossed the membrane.  For further details, assay was performed as described in (Debnath, 
Muthuswamy et al. 2003). 
 
Immunofluorescence  
Hmec-hTERT stable cells were plated on gelatin coated glass coverslip. For stimulation 
experiments, cells were starved overnight and treated with final concentration of EGF 20ng/ml 
for a period of thirty minutes.  Protein lysates were extracted at steady-state, starved and 
stimulated conditions all at the same time for all lines.  Cells were fixed in 2% 
paraformaldehyde 24 hours and permeabilized with 0.2% Triton. Anti-EGFR 
antibody was applied at a 1:300 dilution. Secondary antibody used was at 1:3000 anti-rabbit after 
washing. Coverslips were mounted with Prolong Gold Antifade with DAPI and visualized with a 
Nikon Eclipse 80i with a CoolSnap HQ2 CCD camera. Photographs were taken at both 10X and 
20X magnifications for all cells.  Each group was performed in triplicate and representative 





Anchorage-independent soft agar growth assay 
For soft agar colony formation assays, 2.5 x 10
4
 MCF10A cells or 4.5 x 10 
4
 Hmec-hTERT cells 
were seeded per 60 mm plate with a bottom layer of 0.6% Bacto agar (BD Biosciences) and a top 
layer of 0.3% Bacto agar, both in complete media. Colonies were photographed after 3 weeks of 
incubation and analyzed for MCF10A cells and after 8 weeks for Hmec-hTERT cells.  The total 
number of colonies per cell line was counted per plate.  For MCF10A cell colonies that were too 
many to count total numbers, colonies were counted in at least four different views to calculate 
the average value. Soft agar was performed in triplicate for each sample. 
 
Statistical Analysis 
Proliferation rate and soft agar assays were analyzed using the Chi squared test, with a p-value ≤ 







Screen for gross alterations in EGFR 
EGFR is typically over-expressed in basal-like breast cancer.  Our previous work (shown in 
chapter II) investigated the role of wildtype EGFR in a PTEN-null and DDp53 background in 
normal mammary epithelial cells.  Since only in vitro transformation of the cells, we asked 
whether EGFR was being correctly modeled in our basal breast tumorigenesis model for cell 
lines.  Given the evidence in other cancer types (especially in lung and brain tumors) that EGFR 
over-activity is due to a variety of mutations, our goal was to determine if we could discover any 
alterations in this receptor within the basal-like breast cancer subtype to possibly account for the 
high levels of expression of EGFR observed in vivo in patient samples.  
 
To screen for possible gross alterations of EGFR in breast tumorigenesis, our strategy was to 
examine the integrity of EGFR at the complementary DNA (cDNA) level for an unbiased 
approach.   Given the large size of the EGFR gene, and hence its cDNA, to screen for EGFR 
changes, we designed a minimum of three sets of PCR fragments by dividing up EGFR cDNA 
into three overlapping but closely sized parts that could still be amplified by PCR (Figure 1A).  
The first one third of the gene at the amino terminus was hence called the “5’UTR” most region, 
where the middle part of the gene was called “Middle” and the last one third of the gene ending 





We took the cDNA of all of the basal cell lines aforementioned and ran polymerase chain 
reaction (PCR) experiments to amplify the cDNA of EGFR for each of the three different genetic 
sections we created for EGFR (5’UTR, middle, 3’UTR). We tested a total number of fourteen 
different basal breast cancer cell lines (Figure 1B). The screen was limited to fourteen cell lines 
given that we detected altered PCR fragments early in our screen and decided to start 
characterizing them after analyzing only 14 cell lines (although we did not even get to screen 
many others available). We followed RT-PCR by running the amplified DNA on 1% agarose 
gels along with the amplification of a sample of human normal pooled breast tissue cDNA to 
compare for any shifts in molecular weight of each region amplified to look for gross genetic 
alterations.  
 
Discovery of EGFR variants in five breast cancer cell lines 
We detected five different in-frame fragments in our RT-PCR screen for changes in EGFR in 
basal breast cancer cell lines and a twice as many out-of-frame ones. Each alteration was found 
in a unique breast cancer line in one of the different large fragments that subdivided the cDNA of 
EGFR (Figure 2A).  The PCR amplicons that appeared to have different sizes than the normal 
were cloned and sequenced for careful sequencing analysis. The exact alterations that resulted in 
our sequencing studies have never been reported in normal tissue, breast cancer, and any other 
cancer prior to our study – we found mutants/variants that have large areas deleted in the EGF 
binding domains in the N-terminus end of the receptor, similar but not the same as the 
characterized EGFRVIII mutant where exons 2 through exon 7 are completely deleted in 
glioblastomas (Figure 2B).  This truncated receptor is ligand-independent and it has been shown 
to be constitutively active in tumors of glial origin and in over-expression studies in glial cell 
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lines.  In HCC-1187 (herein termed ‘BL29’ cell line), HCC-1937 (herein termed ‘BL 33’ cell 
line) and L56BR-Cl (herein termed ‘BL54’ cell line), different combinations of exons 2-8 are 
deleted, varying in deletion length from almost 770 nucleotides to about 480 nucleotides (Figure 
4A—C; you can see the specific boundary regions lost).   
 
Furthermore, we found other types of mutations/variations in EGFR – for instance, we detected 
the complete in-frame duplication of exon 20 of EGFR in MDA-MB-436, or herein also termed 
‘BL8’ or ‘ex20d’ mutant cell line (Figure 3A).  Exon 20 mutations, including duplications, do 
exist in primarily lung carcinomas, although the duplications reported in tumors encompass 
partial regions of this exon, not a full duplication as in the case of this breast cancer cell line.  
Yet another class of mutation/variation of EGFR in the screen of breast cancer cell lines was the 
deletion of a large portion of the carboxyl terminus of EGFR ranging from part of exon 20 to part 
of the last exon 28 (HCC-1806 or herein termed ‘BL32’ mutant) (Figure 3B).  Carboxy-terminal 
deletion mutants are found in both glioblastomas and in some rarer cases, in breast cancer. 
Therefore, the region where this mutation was found in a breast cancer cell line has already been 
reported to occur in tumors, emphasizing the relevance of these findings in breast cancer cells. 
 
Detection of stable-expression of novel EGFR variants expressed in mammary cells 
After we generated retroviral expression vectors for each of the variants, we confirmed whether 
the altered EGFR proteins were expressed after transduction of MCF10A and HMEC-hTERT 
cells (Figure 5A—B).  Interestingly, the first blot of Figure 5A shows that cells seem to need to 
be growing in medium containing all of the necessary growth factors for the mutant forms of 
EGFR to be expressed more robustly (the variant/mutant EGFR bands are lower than the 
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wildtype EGFR that runs around 175kDa – please see EGFR-VIII band for reference). However, 
it is important to note that the over-expressed mutant forms of EGFR are still expressed even 
under complete starvation in an approximately 1:1 ratio with the wildtype EGFR protein.  Figure 
5B shows the EGFR variants run in a lower percentage gel to show the separation of the 
wildtype versus the mutant bands in a clearer manner. 
 
Of note, we could not yet detect the mutant for BL 32 BBC cell line because the EGFR antibody 
used detects the exact region on the C-terminus of EGFR that is found deleted. Therefore, all we 
can detect is the regular form of EGFR. We have tried troubleshooting by using N-terminus 
EGFR antibodies but we have not yet been successful, although there are other N-terminus 
EGFR antibodies that we are currently testing to see if it works to detect protein from the BL 32 
mutant in MCF10A and HMEC-hTERT cells.  Even though we cannot current validate whether 
the truncated BL32 EGFR variant is being expressed, we do show that this variant, when over-
expressed in mammary epithelial cells, causes cells to grow better under certain conditions 
(proliferation assay will be discussed below). 
 
We chose an alternative method to detect the endogenous exon 20 duplication variant found in 
MDA-MB-436 cell line by analyzing copy number gain from array comparative genomic 
hybridization (aCGH) data.  We asked whether we could indeed detect higher number/density of 
probes around the region of exon 20 in EGFR.  As Figure 5C shows, we found a cluster of 
probes suggesting a gain of copy number around the region surrounding exon 20 of the receptor, 
which could be indicative of duplication of exon 20 of EGFR (exon 20 area is indicated with an 
arrow). Our aCGH analysis on this cell line was performed by two independent experiments and 
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both times we found copy number gain corresponding to exon 20 (only showing our higher 
density aCGH data).  Indeed, we were able to demonstrate that there is copy number gain in the 
area around exon 20 of EGFR.  
 
Furthermore, when we asked the relevance of finding a BBC cell line with a whole exon 20 
duplication, we looked to see if this region was conserved evolutionarily.  Indeed, Hank et al 
group’s showed that EGFR kinase domains are highly conserved with some of the other tyrosine 
kinase receptors and when we map the exact exon 20 region.  We can extrapolate why a cancer 
cell line would favor this exon to be duplicated. Duplication of exon 20 is also not known to 
occur in cancer cells and thus it is giving the cells an advantage to grow and proliferate. 
 
Cell compartment location of EGFR variants upon EGF stimulation 
Given that signal termination of activated EGFR complexes is not only an important aspect of 
EGFR signaling but tightly controlled to avoid undesired cellular over-stimulation, we asked 
whether any of these novel EGFR mutants could have a different response to ligand stimulation 
as compared to wildtype EGFR protein. We know that when a cell is over-stimulated with EGF, 
receptors are brought inside the cell to early endosome compartments laying just outside the 
nucleus for the receptors either to be degraded to attenuate the signal (negative feedback loop) or 
to be re-packaged (receptor recycling) to go back to the cell surface to be active again. 
Determining the localization of the novel EGFR variants within the cell upon stimulation could 




Indeed, when we performed immunofluorescence in HMEC-hTERT cells over-expressing either 
wt EGFR, empty vector, BL29 or exon 20 duplication variants, we observed loss of congregation 
of EGFR staining in perinuclear regions in the cells over-expressing BL29 variant, as compared 
to wt EGFR or endogenous EGFR only (Figure 6 A—D). This is in accordance with previous 
data showing that EGFR-VIII, an EGFR mutant that lacks some of the same overlapping exons 
in the extracellular domain of EGFR, also stays in the cellular surface and does not get degraded 
when challenged with EGF (Wong, Ruppert et al. 1992) . Thus our BL29 mutant is showing a 
very similar behavior to a known potent oncogenic EGFR.  This lack of proper 
recycling/degradation is not observed in cells expressing exon 20 duplication under the same 
conditions (Figure 6C). 
 
Signaling response of EGFR variants  
We inquired whether EGF stimulation would elicit a different response in the EGFR mutants 
since we know that EGF is one of the main ligands that targets EGF receptors to lead to an array 
of cellular functions such as higher proliferation, decrease in apoptosis, and increased survival. 
Our hypothesis is that if one of these new EGFR mutants are hyper-active or acting somehow in 
a way to stimulate the signaling pathway downstream of EGFR, such as the AKT pathway, that 
we would see it by treating cells with EGF after 24hr starvation and collecting protein lysates at 
various time points.  
 
When we performed EGF stimulation in the different MCF10A cell lines that over-express either 
the empty vector, wildtype EGFR, our positive control EGFR-VIII, and two of the EGFR-VIII 
like mutants, BL 29 and BL33, we were surprised that wt EGFR alone causes the highest 
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phosphorylation of the receptor itself at residue tyrosine-1173 (Figure 7A—D).  Upon EGF 
stimulation over time, we noticed that the variant truncated EGFR proteins, namely EGFR-VIII, 
BL33 and BL29, stayed unchanged regardless of the presence or absence of EGF, while the 
endogenous wt EGFR in these three lines do show to be regulated by EGF stimulation. 
 
When we analyzed signaling downstream of EGFR via either the AKT or ERK pathways, we 
found some differences with the mutant EGFR expressing cells. Even though EGFR receptor 
itself in the mutants analyzed did not get activated at residue tyrosine 1173 to the same high level 
as the wt EGFR alone (in fact, this level of activation is reflected more like the basal level of 
EGFR phosphorylation upon EGF stimulation seen in the empty control line), we did see a large 
delta in phosphorylation of AKT (serine 473) in the two newly identified variants as well as with 
activated ERK (pERK1/1). Interestingly, the signaling response to EGF stimulation in the BL29 
and BL33 variants was very similar to the response by EGFR-VIII. 
 
Furthermore, we asked what the signaling response to EGF stimulation would be when any of 
the EGFR-VIII like variants would be expressed in our previously described ‘triple modified’ 
model of MCF10As that are lacking PTEN and over-expressing a dominant negative form of p53 
(Chapter II) (Figure 8).  Instead of expressing wt EGFR, we stably introduced either our positive 
control EGFR-VIII or BL33 variant (as a representation of one of the three EGFR-VIII like 
variants). We compared EGF signaling response to our original line expressing wildtype EGFR 
to see if there would be any enhanced signaling response by expressing a mutant form of the 




We found that MCF10A-triple modified cells with BL33 mutant behaved in the same fashion as 
EGFRV-III when analyzed for AKT and ERK signaling (compare Figure 8A with B).  Moreover, 
we noticed that level of activation of EGFR (residue Y1173) was just as mild in the BL33 in the 
triple modified background as it was in the MCF10A alone background.  Strikingly, however, we 
were able to detect the phosphorylated truncated variant form of BL33 at residue 1173, unlike 
when this BL33 mutant was expressed alone in MCF10A cells, without the loss of PTEN and 
expression of DNp53.  Perhaps the genetic alterations in the background of the triple modified 
cells aid in the mutant BL33 receptor phosphorylation.  
 
Given the mild response to EGF-stimulation and the possibility that EGF might not be the only 
possible ligand that can stimulate the novel EGFR variants, and we sought to challenge the novel 
EGFR variants by analyzing how long activated EGFR remained after starvation.  We compared 
the response of ex20d and BL29 variants to that of endogenous EGFR (empty control) when 
cells expressing the different constructs were starved for either 10 minutes or 30 minutes (Figure 
8C).  We found that only the cells expressing either one of the mutants were able to sustain 
EGFR activation as measured by phosphorylation at residue Y1173.   
 
Growth rate differences in cells over-expressing EGFR variants under different stimuli  
To understand if any of the novel EGFR variants are dependent on specific ligands to cause 
growth advantage in vitro, we tested different growth media conditions to find the conditions at 
which these mutants might be more activated: semi-starved growth media (5% growth factors 
only), semi-complete growth media (50% of total growth media), and EGF ligand or insulin 




In Figure 9, we show that all but BL33 variant grow significantly better in semi-starved media 
than when compared to cells over-expressing wt EGFR or empty control alone. However, when 
the same set of cells lines were grown with ten-fold higher level of growth factors as compared 
to the previous experiment, we see that now cells expressing most of the EGFR mutants do not 
show greater growth rate advantage over their wt EGFR counterpart (see Figure 10).  This effect 
is similar to what we observed when cells over-expressing the EGFR variants are grown in 
complete (100%) media, thus suggesting just 50% growth factor already is enough to saturate the 
media with growth factors to attenuate the growth advantage that could otherwise be detected. 
We also examined if withdrawing either EGF or insulin from culture media for HMEC-hTERT 
cells over-expressing each EGFR mutant would allow cells to grow better than wildtype EGFR.  
Figures 11 and 12 show that lack of EGF or insulin did not confer any of the mutants a 
significant growth advantage in culture.  
 
BL29 variant of EGFR allows for invasive and growth-anchorage independence 
After observing that in semi-starved conditions that most EGFR variants had a growth 
advantage, and that some of the variants could sustain activated EGFR signaling after starvation, 
we were interested in knowing if any of these mutants could influence migratory rate and 
invasive properties of HMEC-hTERT cells.  In Figure 13 A—B, we show that only BL29 
significantly allows for migration/invasion through matrigel as compared to controls of empty 
vector or wt EGFR alone.  Furthermore, given the variant BL29’s ability to invade matrigel, we 
performed a soft agar assay to test its ability to grow in an anchorage-independent fashion 
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(Figure 13C).  Our results show that only BL29 is able to form colonies when expressed alone in 








We sought out to understand and better characterize EGFR to explain how the frequent up-
regulation of EGFR in basal-like breast tumor samples occurs. There is no convincing published 
data in the literature that EGFR is not altered in basal-like breast cancer, even though we know 
this subtype of BC is up-regulated at the protein level by immunohistochemistry analysis of 
tumor samples (Spyratos, Delarue et al. 1990, Yarden and Sliwkowski 2001). We report here 
five novel variants of EGFR that were discovered in a cDNA screen derived from BBC cell lines 
and our characterization of most of them.   
 
The variants of EGFR we discovered are completely novel EGFR mutants that have not been 
reported in the literature to naturally occur either in cancer cell lines or in primary tumors.  
However, the types of alterations (the areas which the receptor is changed) have been reported 
prior to this work in a variety of tumors.  Specifically, three of the variants (namely, BL29, BL33 
and BL54) have in-frame deletions spanning a number of the exons that overlap with the ligand-
binding domain of this receptor.  Interestingly, this class of alteration of EGFR is found in 
tumors.  The most well-known of them, EGFR-VIII, is highly oncogenic in glioblastoma (Wong, 
Ruppert et al. 1992, Gan, Kaye et al. 2009).  EGFR-VIII is a ligand –independent truncated 
receptor that has exons 2 through 7 deleted in the N-terminal end of the protein (Wong, Ruppert 
et al. 1992).  Del Vecchio and colleagues describe a novel role for EGFR-VIII in invasive breast 
cancer (Del Vecchio, Jensen et al. 2012).  They show that in cancers where EGFR-VIII is 
expressed, there is an increase in the expression of genes associated with self-renewal and 
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epithelial-to-mesenchymal transition as well as a higher portion of stem-like cells.  This study is 
one of the most definitive characterization of the role of EGFR-VIII in breast cancer.  Therefore, 
future examination of our BL29 variant for properties of increased stem-cell phenotype will be 
important to understand if there are functional differences between EGFR-VIII and our reported 
BL29 variant that is structurally very similar to the glioblastoma mutant.  
 
Another class of alteration we report here in the EGFR cDNA of breast cancer cell is deletion of 
the carboxy-terminal end of the receptor, as represented by the BL32 variant in our screen.  
Again, structural variants containing deletions in this area of the receptor have been previously 
reported – including EGFR-vIVa, EGFR-vIVb, mLEEK EGFR, among other carboxy-terminal 
domain (CTD) mutants (Pines, Huang et al. 2010, Cho, Pastorino et al. 2011, Piccione, Lieu et 
al. 2012). These mutants have shown to have a variety of novel functions – for instance, 
mLEEK, a variant EGFR that lacks the extra-cytoplasmic, the transmembrane and the tyrosine 
kinase domain, can translocate to the nucleus to function as a transcription factor and activate 
endoplasmic reticulum stress response (Piccione, Lieu et al. 2012). This variant is upregulated in 
cancers and down-regulating it in tumors leads to caspase-mediated cell death.  Another CTD 
deletion variant of EGFR, described by Cho and colleagues, and missing exon 27, can induce 
tumorigenesis in vitro and in vivo, even in the absence of ligand or lack of evidence for receptor 
phosphorylation (Cho, Pastorino et al. 2011).  Importantly, the exon 27-deleted variant was 
sensitive to three different EGFR inhibitors.  Much of the function of our CTD deleted BL32 
variant is unknown still, although we know it can grow well in the presence of low levels of 
growth factors.  Perhaps our breast cancer CTD variant acts more like the glioblastoma CTD 
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(Cho et al) given it could grow slightly better than wildtype EGFR in the absence of EGF or 
insulin. Further experiments are needed to more precisely delineate the role of our CTD variant. 
 
Moreover, the third type of mutation identified in our screen was duplication of exon 20. Exon 
20 lies within the kinase domain of EGFR and thus we hypothesized that this region was 
possibly conserved evolutionarily given the importance of the kinase domain to the function and 
activation of EGFR by containing multiple tyrosine residues that are phosphorylated when EGFR 
is dimerized (Yarden 2001). Indeed, Hank and colleagues showed that the EGFR kinase domain 
is highly conserved along with other tyrosine kinase receptors (Hanks, Quinn et al. 1988). 
Therefore, when we map the exact region for this duplicated exon, we can extrapolate why a 
cancer cell line would favor this exon to be duplicated. Duplication of exon 20 has also been 
highly annotated in other cancers, such as glioblastoma and lung cancer, though this type of 
alteration is more typically found in the latter type of cancer where it can account for 
approximately 4% of the mutations in EGFR (Yasuda, Kobayashi et al. 2012).  However, exon 
20 has only been reported thus far to be partially duplicated, unlike our full exon 20 duplication 
variant.  Of note, alterations in the tyrosine kinase domain of EGFR have been shown to 
contribute to drug resistance in non-small cell lung cancer (Lynch, Bell et al. 2004, Paez, Janne 
et al. 2004, Yasuda, Kobayashi et al. 2012).  Also, it has been postulated that exon 20 
duplications allow for the activation pocket of the kinase domain to be open constitutively and 
this could account for the sustained phosphorylation of the ex20d variant under starved 




Lastly, our work highlights the importance going forth considering that EGFR may have 
different variants in not only basal breast cancer, but in other cancers for which its upregulation 
has not been yet understood.  The variants may have strong implication for drug therapies that 
target EGFR (from the large array of EGFR inhibitors currently in the market). Patients 
expressing either the same or a similar variation of EGFR in their BC may benefit from drug 











Figure 1. Scheme for analyzing the large cDNA of EGFR for alterations in a panel of breast cancer 
cell lines of the basal-like subtype.   
(A) EGFR is composed of 28 exons and its cDNA is 3.48 kilobases long, therefore, the cDNA was 
subdivided into three overlapping smaller regions (1.54 kb, 1.42 kb, and 1.41 kb, respectively from 5’ to 
3’) to be amplified by reverse-transcriptase PCR to screen for gross genetic alterations in this gene.  (B) 
The breast cancer cell lines that were screened for EGFR alterations are all from the basal-like subtype of 





Figure 2.  Alterations discovered in the ligand-biding domain of EGFR discovered in breast cancer 
cell lines.  
(A) The table illustrates the positive results in five different breast cancer cell lines for each of three 
regions of the cDNA for EGFR.  ‘Normal’ indicates that the size of the PCR band was the same as the 
size for amplification of the same region for control cDNA from a pool of human non-transformed 
mammary epithelial cells. (B) Three of the novel variants of EGFR in the cDNA screen were compared to 
the common alteration found in glioblastoma of a constitutively active EGFR mutant, EGFR-VIII.  
Although EGFR-VIII is the largest of all cited variants, the parameters that are altered in the novel breast 
cancer EGFR variants are similar to those of EGFR-VIII.  The variant named EGFR-BL29 was the one 




Figure 3. Schematic illustration of two novel variants of EGFR that are altered either in the 
tyrosine kinase domain or the carboxy-terminal domain of this receptor.  
(A) A cartoon depicting the wildtype (WT) form of the EGFR receptor across the surface of a cell 
membrane (red lines indicating exons in kinase domain) as compared to a cartoon of a novel variant of 
EGFR containing an in-frame whole exon duplication of exon 20 of EGFR that lies within the kinase 
domain (the blue line).  This duplication was found in the MDA-MB-436 cell line.  RT-PCR of this cell 
line showing the higher molecular band where exon 20 duplication was found. (B) A different variant of 
EGFR discovered has a large in-frame duplication that spans part of exon 20 within the kinase domain to 
near the end of the last exon, exon 28. This alteration was found in the HCC-1806 breast cancer cell line 







Figure 4. Cartoon illustrations of the novel variants of EGFR where alteration is localized to the 
extracellular domain.   
The variant form of EGFR from basal-like breast cancer cell lines are compared to the wildtype form of 
EGFR (in the middle) and to the known extracellular domain mutant, EGFR-VIII (on the left). (A) 
Depiction of the ligand-binding domain deleted variant, BL29, showing the loss of a total of 773 
nucleotides, which is almost the size same as EGFR-VIII.  One main difference between the known 
EGFR-VIII mutant and BL29 variant in breast cancer (HCC-1187) is the lack of a newly formed amino 
acid in the new junction formed from the deletion that is found in EGFR-VIII but not in BL29. (B) The 
second largest deletion mutant in the EGFR ligand-binding domain is BL33 (HCC-1937 breast cancer cell 
line).  (C) Illustration of a third but shortest of all novel deletion mutants in the N-terminus of EGFR – BL 
54 variant (L56BR breast cancer cell line). The diagrams are not to scale. (A-C) Show the results for RT-





Figure 5.  Expression of the novel EGFR variants in normal mammary epithelial cells.   
(A) Western blot analysis of the cloned EGFR variants stably over-expressed into MCF10A cells. Empty 
vector (EV) and over-expression of wildtype (WT) EGFR are negative controls for EGFR alteration 
whereas the EGFR-VIII cells are positive control (truncated mutant is about 145 kDa).  Stable expression 
of EGFR variants is validated for most of the variants, except for BL32 where the antibody tags the 
protein in the region that is deleted in this variant. Expression of the variants is tested under both steady 
state and O/N starved conditions.  (B) Validation of EGFR variants in Hmec-hTERT. (C) aCGH assay on 
MDM-MB-436 cells to validate duplication in exon 20 in EGFR.  Cartoon of EGFR gene is represented 
above the diagram to represent approximate positions of probes.  (D) Strategy of primer design to detect 
in tandem exon 20 duplication in genomic DNA such that only if duplication is found (as was confirmed 






Figure 6.  Immunofluorescence of cells expressing novel EGFR variants for detection of localization 
differences between wildtype and variant receptors.   
Hmec-hTERT cells over-expressing either controls (empty vector, EV; wildtype EGFR, WT) or EGFR 
variants to detect differences of location of EGFR when cells are under steady state, starved overnight, 
and stimulated by growth factors after overnight starvation.  (A—D) Under physiological conditions, as 
shown by EV and WT (A and B), activated EGFR upon post ligand stimulation undergoes signal 
termination by being endocytosed to the perinuclear regions of the cell.  (C) Variant expressing a full 
exon duplication in the kinase domain of EGFR (ex20d) showed a similar phenotype as WT, however, 
(D) the variant that has a deletion in the ligand-binding domain of EGFR did not show as pronounced 
accumulation of EGFR in vesicles surrounding the nucleus.  EGFR is tagged by antibody that is in red 
and the nucleus is visible in purple by staining the cells with DAPI staining.  Inset photograph is in 20X 





Figure 7. Signaling activation post EGF stimulation of mammary epithelial cells over-expressing 
novel EGFR variants.  
MCF10A cells were completely starved overnight and stimulated with EGF (20 ng/ul) for an increasing 
amount of time (30”, 5’, 20’, and 60’). Whole protein lysates were extracted.  (A—D) Variants were 
compared against cells over-expressing wildtype (WT) EGFR.  WT EGFR signaling is more pronounced 
than endogenous EGFR (EV) cells, as expected, though both show that EGFR is down-regulated via 
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degradation as early as 5’ after EGFR is bound to its ligand EGF.  Both the receptor (at residue Y1173) 
and the AKT (at serine 473 residue) and ERK pathways were activated with EGF stimulation.  (B) The 
mutant EGFR-VIII protein levels did not change with EGF stimulation when probed with total EGFR 
antibody, whereas the endogenous EGFR in the cells did attenuate total EGFR in the cells, as expected.  
Activation of EGFR-VIII was not ligand-independent as the phosphorylation of the receptor increased 
with longer the EGF stimulation.  (C—D) Both variants BL29 and BL33 of EGFR responded in a similar 
fashion as the positive control for EGFR mutant, EGFR-VIII.  Neither EGFR variant was down-regulated 
upon stimulation of EGF over time.  Like EGFR-VIII, however, both BL29 and BL33 variants responded 
by activating downstream effectors, AKT and ERK, to the same level as wildtype EGFR, even though 


















Figure 8. Signaling activation of mammary epithelial cells over-expressing novel EGFR variants 
with or without loss of PTEN and expression of dominant negative p53 (DDp53).   
(A—B) MCF10A cells (MCF10Ap-PTEN-/-DDp53) expressing different forms of EGFR were starved 
overnight and stimulated with EGF (20 ng/ul) for an increasing amount of time (30”, 5’, 20’, and 60’). 
Whole protein lysates were extracted.  (A) Either wildtype (WT) or known oncogenic EGFR mutant 
(EGFR-VIII) were stably expressed into the cells and probed for various antibodies. Truncated mutant 
does not get degraded with EGF stimulation in this background unlike the endogenous and over-
expressed WT EGFR.  Activation of EGFR (Y1173) was lower in the EGFR-VIII expressing cells though 
+  -- --  +  -- --  +  --  -- 
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the downstream signaling for both AKT and ERK were higher for the known mutant. (B) Over-expression 
of novel EGFR variant BL33 in the MCF10A-PTEN-/-DDp53 background also showed lack of EGFR 
degradation upon EGF stimulation over time.  This variant had a similar phenotype for activation of 
EGFR, AKT and ERK as described for EGFR-VIII. (C) Hmec-hTERT cells stably over-expressed either 
empty vector control (EV), the exon 20 duplication variant (ex20d) or BL29 EGFR (ligand-binding 
domain truncated mutant) were starved for either 0’, 10’ or 30’ before total protein lysates were harvested 
for signaling.  Activation of EGFR (Y1173) remains even after withdrawal of growth factors for a 
minimum of thirty minutes for both ex20d and BL29 variants of EGFR as compared to EV. Vinculin was 







































Figure 9.  Most of the variants of EGFR are able to grow better in the presence of semi-starvation 
media over time as compared to wildtype EGFR.   
Proliferation rate compared between Hmec-hTERT cells stably over-expressing different forms of EGFR 
in the presence of medium containing only 5% of growth serum (semi-starved conditions).  Each variant 
was compared to growth of cells expressing either empty vector control (Empty) or wildtype EGFR (wt).  
(A—F) Cells expressing controls (Empty and wt) grew at a similar rate over a period of six days.  (A) 
Known oncogenic EGFR control, EGFR-VIII, grew better in semi-starved conditions.  (B—D) Variants 
for exon 20 duplication (ex20d), BL29 (ligand-binding domain truncation) and BL32 (carboxy-terminal 
domain truncation) grew at a similar rate as positive control under the same conditions.  (E) Variant BL33 
(also a ligand-binding domain truncated EGFR) did not show significant growth advantage over control 
cells and (D) BL54 (ligand-binding domain truncation) showed a mild to almost no growth advantage 
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over control cells.  Each cell line was analyzed in replicates of six wells and standard deviation was 





























Figure 10.  No significant growth advantage of cells expressing variants of EGFR over wildtype 
EGFR-expressing cells in media containing semi-complete levels of growth factors.   
Proliferation rate compared between Hmec-hTERT cells stably over-expressing different forms of EGFR 
in the presence of medium containing 50% of regular growth serum (semi-complete conditions).  Each 
variant was compared to growth of cells expressing wildtype EGFR (wt).  (A—F) Cells expressing either 
oncogenic EGFR control (A) or any of the five novel variants of EGFR (B –F) grew slightly better to 
almost the same rate as cells expressing wildtype EGFR under the same growth conditions. Each cell line 













Figure 11.  Expression of novel EGFR variants did not show proliferative advantage in the absence 
of ligand EGF.   
Proliferation rate compared between Hmec-hTERT cells stably over-expressing different forms of EGFR 
in the presence of medium lacking EGF.  Each variant was compared to growth of cells expressing empty 
vector (Empty) and wildtype EGFR (wt), both of which grew statistically at the same rate.  (A—F) Cells 
over-expressing either oncogenic EGFR control (A) or any of the five novel variants of EGFR (B –F) 
proliferated at approximately a similar rate as cells expressing wildtype EGFR or empty vector under the 








Figure 12.  Insulin withdrawal does not confer proliferative advantage in most novel EGFR 
variants.   
Proliferation rate compared between Hmec-hTERT cells stably over-expressing different forms of EGFR 
in the presence of medium lacking insulin.  Each variant was compared to growth of cells expressing 
either empty vector control (Empty) or wildtype EGFR (wt).  (A—F) Cells expressing controls (Empty 
and wt) grew at a similar rate over a period of six days.  (A) Oncogenic EGFR control, EGFR-VIII, 
showed slight increase in growth rate.  (B—F) Variants for exon 20 duplication (ex20d) and BL32 
(carboxy-terminal domain truncation) grew faster than positive controls under the same conditions, 
though BL29 (ligand-binding domain truncation), BL33 (also a ligand-binding domain truncated EGFR) 
and BL54 (ligand-binding domain truncation) showed no growth advantage over control cells.  Each cell 





Figure 13.  BL29 EGFR variant affects migration, invasion and transformation.   
Hmec-hTERT cells over-expressing different forms of novel EGFR variants were examined in transwell 
and soft agar assays.  Controls were either empty control (empty), wildtype EGFR (WT) and/or 
oncogenic EGFR-VIII.  (A—B) The same number of cells was seeded in the inner chamber of a transwell 
that was coated with matrigel to assay both migratory and invasive properties of cells.  Only the cells 
over-expressing the BL29 variant was able to migrate and invade statistically more than any of the other 
cell lines, including the EGFRVIII positive control.  (C) Cells were plated onto semi-solid agar plates to 
be examined for their ability to grow over time in an anchorage-independent manner, a property of 
transformed cells.  As with the transwell assay, only the cells expressing BL29 variant grew colonies. 
Plates were incubated for a period of 60 days prior to counting the number of colonies on each plate.  For 










 We optimized and successfully infected our MCF10A and HMEC-hTERT cells with 
different cocktails of lenti- and retro-viruses for robust expression of the genetic changes 
of interest 
 
 We engineered new MCF10A cells that are null for PTEN to also express DDp53 and 
EGFR expression to test for their ability to show whether their oncogenic potential would 
improve for both in vitro and in vivo assays 
 
 We confirmed with published data that MCF10A-PTEN null clones alone have a great 
advantage of growth in media without any growth factor supplement over an extended 
period of time  
 
 The activation of AKT by the phosphorylation of S473 and T308 residues were 
accentuated when MCF10A cells lost PTEN expression and/or expressed DDp53 and/or 
EGFR as shown by two different PTEN null clones 
 
 We showed that MCF10A-PTEN null clones when also expressed with DDp53 and/or 
wildtype EGFR can grow faster than their parental MCF10A cell line 
 
 We analyzed a panel of basal breast cancer cell lines for alterations in the EGFR gene at 
the cDNA level by sequencing EGFR in large regions by RT-PCR to find any gross 
genetic alterations 
 
 After screening a panel of basal breast cancer cell lines, we identified 5 unique putative 
new EGFR in-frame alterations that have never been reported  
 
 Novel EGFR variants range from three large in-frame multiple-exon-spanning deletions 
of the amino-terminal end of the protein, as well as one large carboxy-terminal end 
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deletion and one complete duplication in tandem of exon 20 in the tyrosine kinase 
domain of EGFR 
 
 We performed high density array aCGH and validated the gross genetic alteration in 
MDA-MB-436 BBC cell line – a complete in-tandem duplication of exon 20 of EGFR  
 
 We cloned the five novel variant forms of EGFR into pBABE-PURO retroviral vectors to 
study each of their role in MCF10A cells and HMEC-hTERT cells 
 
 We confirmed that most of the EGFR variants are indeed expressed as proteins in cells 
when they are over-expressed 
 
 We studied the EGFR variants by analyzing their growth rate in different media 
conditions and showed that all of the variants grow better than over-expressing wildtype 
EGFR in semi-starved media (5% growth factors) in HMEC-hTERT cells 
 
 We stimulated MCF10A cells expressing single EGFR variants starved overnight with 
EGF at various times points to analyze the signaling responses to EGF stimulation and 
found that at the EGFR receptor activation level, there is no evidence of higher activation 
at residue tyrosine-1173; however, we further showed that signaling downstream of 
EGFR is stronger for variants analyzed for activation of AKT and ERK proteins as 
compared to the levels in wt EGFR-expressing cells 
 
 We showed that when the EGFR variants are stably overexpressed in Hmec-hTERT cells, 
and their growth factors and serum are withdrawn for various amounts of time, some of 
the mutants can maintain signaling of EGFR even after thirty minutes of starvation 
whereas control cells cannot show EGFR phosphorylation 
 
 
 We studied how localization might change when each variant of EGFR is singly 
expressed into HMEC-hTERT cells by performing immunofluorescence on EGFR – 
specifically our results suggest that when over-expressing BL 29 EGFR variant 
(discovered in HCC1187 basal breast cancer cell line) in HMEC-hTERT cells, EGFR is 
not localized primarily to the endosome vesicles as part of the normal mechanism for 




 We showed that variant BL 29 conferred mammary cells properties that were stronger 
than wt EGFR for migration and invasion through transwell assay that had matrigel 
coating to test for invasiveness 
 
 We showed that stably over-expressing BL29 EGFR alone in Hmec-hTERT cells is 









INTEGRATING PTEN/EGFR/P53 IN A MODEL FOR BBC  
 
 
One of this dissertation thesis’ goals was set out to dissect the genetic alterations that are needed 
to occur in a normal mammary epithelial cell in order for cell to become fully transformed. Our 
work shows that loss of PTEN, the expression of DDp53 (dominant negative p53 that inactivates 
wildtype p53 functions) and over-expression of the wildtype form of EGFR in the non-
transformed mammary epithelial cell line, MCF10A, can transform this line in vitro but not 
sufficiently in vivo.  
 
More specifically, we showed that loss of PTEN is the most influential single alteration among 
all three of them in epithelial cells and if PTEN is lost but there is over-expression of either 
EGFR or altered p53 (in this case, a dominant negative form, DDp53), then there is a strong 
synergy in growth properties of the cells.  The expression of all three altered genes, however, 
showed the most transforming potential in MCF10A cells, suggesting that EGFR, PTEN and p53 
are likely not overlapping completely in the pathways that they activate.  Our work suggests 
further examination of how PTEN, EGFR and p53 are all directly or indirectly interacting and 






THE IMPACT OF ALTERED EGFR VARIANTS IN BREAST TUMORS  
 
In the attempt to further dissect the main genetic oncoproteins that are necessary for the onset of 
basal breast cancer, we discovered novel variants of EGFR that have never been reported in 
either breast cancer or in any other cancer.  EGFR variants expressing duplication in the 20
th
 
exon of EGFR, lacking large portions of the extracellular domain and intracellular domains have 
been reported, however, the alterations are not identical (Wong, Ruppert et al. 1992, Cho, 
Pastorino et al. 2011, Piccione EC 2011). The screen we deployed targeted BBC cell lines but 
further analysis will be important to identify whether it is only the BBC subtype of cancer that 
contains EGFR variants or if other subtypes may also express alterations in EGFR, even though 
EGFR over-expression is an identifier mainly in the BBC subtype. 
 
We showed that some of the variants, particularly one which had the closest structural identity to 
oncogenic EGFR-VIII expressed in glioblastoma (namely, BL29 variant), showed strong 
oncogenic properties when expressed alone in non-transformed mammary epithelial cells, Hmec-
hTERT.  Interestingly, BL29 is more potent than oncogenic EGFR-VIII in both 
migration/invasion and transformation assay.  However, we are only starting to understand and 
characterize these novel variants – it will exciting to see if any of them can be neomorphic forms 
of EGFR, and thus reveal an interesting new role for EGFR that might not be observed under 
normal physiological conditions when the receptor is wildtype in nature.  
 
There is a possibility that BL29 variant, for instance, can be expressed in our proposed triple 
modified model for BBC tumorigenesis to allow the model to grow tumors in vivo as well 
(Figure 1).  If this scenario is tested and breast tumors do form, we will be able to also study new 
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EGFR variants in a more physiological setting to the mutant EGFR where we might be able to 




Figure 1. Alternative model for BBC tumorigenesis where wt EGFR is replaced with a hyperactive 
variant form of EGFR to allow for in vivo tumor formation.   
Replacing wt EGFR for one of the novel EGFR variants found in BBC cell lines would be a way to test 






THERAPEUTIC RELEVANCE OF THIS WORK   
 
BBC does not currently have targeted therapy and thus it has a very high rate of death for those 
who have it. If these EGFR alterations found in our work, or ones similar to the ones described 
here, are found in primary tumors, then we can start running in vitro screenings for drugs that 
would ideally specifically kill only the cells expressing the EGFR mutants in the hope to find 
targeted therapy for basal-like breast cancer patients. It is possible that the variants would be 





Our work is important for the breast cancer field because it highlights the importance of EGFR in 
breast cancer development.  Until very recently, there was little motivation to investigate altered 
forms of EGFR in breast cancer due to so many publications concluding that EGFR was not 
altered in BBC (Rae, Scheys et al. 2004, Bhargava, Gerald et al. 2005, Reis-Filho, Pinheiro et al. 
2006, Uramoto, Shimokawa et al. 2010, Jacot, Lopez-Crapez et al. 2011, Martin, Botta et al. 
2012).  It has been demonstrated that EGFR can be amplified in a very small percentage of basal-
like breast tumors (1%), one of the least well understood of the subtypes of breast cancer (Ro, 
North et al. 1988). However, in the last few years, the literature on EGFR alterations in breast 
cancer is growing to hopefully motivate scientists to refocus on finding creative ways to detect 
any form of altered EGFR to help explain its role in breast tumorigenesis (Tang, Gong et al. 
2000, Ge, Gong et al. 2002, Weber, Fukino et al. 2005, Teng, Tan et al. 2011, Del Vecchio, 




Therefore, the work presented in this thesis highlights the importance of carefully investigating 
genes that have shown to be correlated with breast cancer, such as EGFR, to accurately be able 
to model its modes of activation in tumorigenesis.  We show that altered forms of EGFR do exist 
in BBC cell lines and, even though these alterations have not been yet documented in primary 
breast tumors, our work strongly suggests that it is important to re-evaluate EGFR in large sets of 
breast tumors, particularly from the basal-subtype.  Moreover, our work showing the 
transforming relationship between EGFR, PTEN and p53 in vitro suggests that future 
experiments replacing a mutant form of EGFR in our BBC cell line model could yield some 
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